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Abbreviation     
                                 
ACE: angiotensin converting enzyme  
AGEPC: acetyl-glyceryl-ether-
phosphorylcholine 
ASM: acid sphingomyelinase 
ALI: acute lung injury 
ARDS: Acute respiratory distress 
syndrome 
AJs: adherens junctions 
ATP: Adenosine-5'-triphosphate 
BAL: bronchoalveolar lavage  
Cav-1: caveolin-1 
CSD: caveolin scaffolding domain 
CBM: caveolin binding motif 
CFTR: cystic fibrosis transmembrane 
conductance regulator 
COX: cyclooxygenase 
COPD: Chronic obstructive pulmonary 
disease 
CTxB: cholera toxin binding subunit 
Ca2+: calcium ion 
DAD: diffuse alveolar damage 
DAG: diacylglycerol 
eNOS: endothelial nitric oxide 
synthase 
ER: endoplasmic reticulum 
FAK: focal adhesion kinase 
FRET: fluorescence resonance energy 
transfer 
FGF: fibroblast growth factor  
GST: glutathione S-transferase  
HMEC: human microvascular 
endothelial cell  
GAP: GTPase-activating protein 
GTP: guanosine triphosphate 
GEF: guanine nucleotide exchange 
factors 
HDL: high density lipoproteins  
HUVECs: human umbilical vein 
endothelial cells 
HUVEC: human umbilical endothelial 
cell 
IP3: inositol trisphosphate 
IPL: isolated perfused rat lung  
IRDS: infant respiratory distress 
syndrome 
IQGAP: IQRas GTPase activating 
protein 
LDL: low-density lipoprotein  
LTC: leukotrienes C 
LTD: leukotrienes D 
LPS: lipopolysaccharide  
MAEC: mouse aortic endothelial cell 
MLCK: myosin light chain kinase 
MLCP: myosin light chain phosphatise 
MAPK: mitogen activated protein 
kinase  
NGF: nerve growth factor  
NOS: nitric oxide synthase 
NO: nitric oxide 
NPD: Niemann-pick disease 
LPS: lipopolysaccharides 
PAEC: pulmonary artery endothelial 
cell 
PAF: platelet activating factor 
PAK: p21-activated kinase 
PAR: Proteaseactivated receptor 
PGE2: Prostaglandin E2  
PKC: Protein kinase C 
PLA2: phospholipase A2 
PLC: phospholipase C 
PMCA: plasma membrane Ca2+-                 
ATPase 
PIP2: phosphotidyl inositol 
bisphosphate 
PTEN: phosphoinositide phosphatase  
ROC: receptor operated channel 
ROCK: Rho-associated protein kinase 
S1P: Sphingosine-1-phosphate 
SERCA: sarco/endoplasmic reticulum 
Ca2+-ATPase 
SNAP: S-nitroso-N-acetyl-penicillamine  
SHP: Src-homology-2-domain-
containing protein tyrosine phosphatise 
SOC: store operated channel 
STIM: Stromal-Interacting Molecule 
TGF: transforming growth factor 
TJs: tight junctions 
TNF-α: tumour necrosis factor-α 
TRPC: canonical transient receptor 
potential channel 
TXA2: thromboxane A2 
VEGF: vascular endothelial growth 
factor 
VSMC: vascular smooth muscle cell
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1 Introduction 
The Lungs, the most essential and important respiration organ in all air-breathing 
animals. In mammals and the more complex life forms, the two lungs are located in 
the chest on either side of the heart. Their principal function is to transport oxygen 
from the atmosphere into the bloodstream, and to release carbon dioxide from the 
bloodstream into the atmosphere. Air progresses through the mouth or nose, and 
travels through the oropharynx, nasopharynx, the larynx, the trachea, and a 
progressively subdividing system of bronchi and bronchioles until it finally reaches 
the alveoli where the gas exchange of carbon dioxide and oxygen takes place [1].  
 
1.1 Concise lung morphology 
Human lungs weight 900 to 1000 g, of which nearly 40% to 50% is blood. At end 
expiration, the gas volume is about 2.5 L, whereas at maximal inspiration it may be 6 
L [2-3]. The human lungs are located in two cavities on each side of the heart. 
Although similar in appearance, the two are not identical. And both are separated into 
lobes by fissures, with three lobes on the right and two on the left [3]. 
 
1.1.2 Airways 
The airways, connecting the atmosphere and the terminal respiratory units, are 
critically important to the lung functions. As seen in figure. 1, the lower airways are 
divided into three major groups: bronchi, membranous bronchioles and respiratory 
bronchioles/gas exchange ducts. The bronchi enter the lungs and branch into a tree-
like appearance. The bronchi branches into bronchioles, respiratory bronchioles and 
eventually to the terminal respiratory units whereas the most of the gas exchange 
progresses [2-4].  
 
1.1.3 Terminal respiratory units 
The terminal respiratory units comprise all alveolar ducts, together with their 
accompanying alveoli. In the human lungs, this unit contains approximately 100 
alveolar ducts and 2000 alveoli and in total there are about 150,000 such units in the 
entire lung. The terminal alveoli are wrapped by the capillaries with a total surface 
area of 70 m2 in humans [4]. The gas exchange can be accomplished in this so-
called alveolar-capillary unit which is built up by several thin layers: the endothelium 
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facing the blood, the interstitium and the alveolar epithelium facing the air. In human 
lungs, the total alveolar surface is about 50-100 m2 [5]. 
In the terminal respiratory units, gas-phase diffusion is so rapid that the partial 
pressures of oxygen and carbon dioxide are even throughout the unit.  Oxygen will 
diffuse from the gas adjacent to the alveolar wall through the air-blood barrier into the 
red blood cells flowing in the capillaries, where it combines with haemoglobin; 
meanwhile the carbon dioxide diffuses in the opposite direction [3].   
 
1.1.4 Pulmonary circulation 
The pulmonary circulation starts at the right ventricle though the pulmonary artery 
and ends in the left ventricle with oxygen enriched arterial blood from the lung. The 
normal pulmonary circulation is a low-resistance and low-pressure circuit. In humans, 
the pulmonary artery enters each lung at the hilum in a loose connective tissue 
adjacent to the main bronchus. The pulmonary artery travels adjacent to and 
branches with each airway generation down to the respiratory bronchiole. The 
arrangements of the pulmonary arteries and the airways are a continual reminder of 
the relationship between ventilation and perfusion that determines the efficiency of 
normal lung functions [4].  
The capillary network is long and crosses one or several alveoli of the terminal 
respiratory unit. Theoretically, gas exchange may occur through the thin wall of 
almost any pulmonary vessel at normal alveolar oxygen tensions, however, only little 
oxygen and carbon dioxide exchange occurs before the true capillaries. This could 
be explained by the rapid linear velocity of blood flow in pulmonary arterioles [6]. As 
blood enters the vast alveolar wall capillary network, its velocity slows, and the 
majority of gas exchange occurs in the sufficient time and huge exchange surface.  
 
1.1.5 Type I and type ll cells 
The alveolar wall is mainly formed of flat alveolar type l pneumocytes and cuboidal 
type II pneumocytes. Type II cells attach via tight junctions to neighbouring type I 
cells to form a relatively impermeable seal between alveolar air and connective tissue 
spaces. The function of type I cells is to facilitate gas exchange, but the type I cells 
also express water channels and have remarkable water permeability [7]. 
Furthermore these cells also express epithelial Na+ channels and membrane Na+/K+-
ATPase. These observations collectively imply that type I cells may also play a major 
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role in pulmonary water fluxes [8-9]. The type II cell is the major synthesizing and 
secreting factory of the alveolar epithelium and implements epithelial repair via its 
ability to proliferate. The proteins produced by the type II cell include surfactant-
associated proteins that affect surfactant recycling, adsorption of surfactant lipids to 
an air-liquid interface, and immuno-modulating functions, receptors for growth 
factors, growth factors; enzymes, matrix proteins, epithelial mucins, and others. The 
presence in type II cells of various ion channels and transporters supports earlier 
evidence that type II cells are actively involved in fluid resorption and trans-epithelial 
water fluxes [10-11]. 
Type II cells can proliferate and generate both new type II and new type I cells, but 
type I cells are believed to be incapable of cell division. During post-injury repair, the 
postmitotic progeny of type II cells can differentiate into type I cells with normal 
morphology, a process that is also presumed to occur during the normal turnover of 
type I cells [1, 4]. 
 
1.1.6 Lung endothelium 
Pulmonary capillaries are lined by continuous (non-fenestrated) endothelial cells. 
These attenuated cells have an individual area of 1000 to 3000 µm2 and an average 
volume of 600 µm3 [4]. These endothelial cells form a semi-permeable barrier which 
is very important in regulating and controlling the macromolecules and fluid passing. 
Pulmonary capillary endothelial cells have organelles involved in endocytosis through 
caveolae, multivesicular bodies, and lysosomes. These endocytic apparatus appears 
to participate in receptor-mediated uptake and transport of albumin, low-density 
lipoproteins, and thyroxine [12-13]. Another route for passage of solutes and water is 
between adjacent endothelial cells and this passage route is restricted by specialized 
junctional complexes called adhering junctions (AJs) [14-15]. 
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Fig. 1: Complete respiratory system, Adapted from Wikipedia, http://en.wikipedia.org/ 
wiki/Respiratory_system, last reviewed 23.09.2010. 
 
1.2 Acute respiratory distress syndrome (ARDS) 
1.2.1 Definition and background 
Acute respiratory distress syndrome (ARDS), also known as respiratory distress 
syndrome (RDS) as its name suggests, is a syndrome, reflecting a series of clinical 
and physiologic observations caused by a variety of direct and indirect issues [1, 4].  
ARDS is characterized by inflammation of the lung parenchyma leading to impaired 
gas exchange with concomitant systemic release of inflammatory mediators causing 
inflammation and hypoxemia and is frequently part of a multiple organ failure 
syndrome. This condition is often fatal, usually requiring mechanical ventilation and 
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admission to an intensive care unit. A less severe form is called acute lung injury 
(ALI) [4]. 
The first description of ARDS appeared in a remarkable case study in 1967 [16]. 
Ashbaugh and colleagues described 12 patients in age 11 to 48, who presented 
respiratory distress, hypoxemic respiratory failure, and patchy bilateral infiltrates on 
chest radiographs. The syndrome was characterized by rapid onset, as most of the 
patients developed respiratory distress within 48 to 72 hours. Most of the cases were 
preceded by severe trauma or viral infection. Many patients required positive-
pressure ventilation and exhibited low respiratory system compliance. This syndrome 
was initially termed the adult respiratory distress syndrome, to distinguish it from the 
respiratory distress syndrome seen in infant (IRDS). Subsequently, by recognizing 
that this type of pulmonary edema can also developed in children, it was renamed the 
acute respiratory distress syndrome [4, 16]. 
In 1994, a consensus conference of American and European investigators published 
their definition of ARDS, which has since been widely adopted. Aiming for simplicity, 
ARDS was defined as a syndrome of acute onset, with bilateral infiltrates on chest 
radiography consistent with pulmonary edema, pulmonary artery occlusion pressure 
less than or equal to 18 mm Hg (or absence of clinical evidence of left atrial 
hypertension), and hypoxemia as measured by the ratio of the arterial partial 
pressure of oxygen (PaO2) to the fraction of oxygen inspired (FiO2). Recognizing the 
spectrum of severity of the disease, the consensus panel recommended that a PaO2/ 
FiO2 ratio of less than or equal to 300 define an entity termed acute lung injury (ALI). 
ARDS, the most severe form of ALI was defined as occurring if the PaO2/FiO2 ratio is 
less than or equal to 200 [17]. 
To summarize and simplify, ARDS is an acute (rapid onset) syndrome (collection of 
symptoms) that affects the lungs widely and results in a severe oxygenation defect, 
but without heart failure. 
 
1.2.2 Pathophysiology of ARDS 
In the past, ARDS has also been called non-cardiogenic pulmonary edema, which is 
not entirely correct but nonetheless is descriptive.  Unlike cardiogenic pulmonary 
edema, the edema in ADRS is caused by increased permeability though the alveolar-
capillary barrier. Following endothelial and epithelial damage, a protein-rich fluid 
floods into the alveolar spaces. Type II cells are damaged, causes surfactant 
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production decrease and alveoli collapse. This leads to decreased respiratory system 
compliance and profound hypoxemia.  
The pathologic features of ARDS are described in three stages: The first one has 
been termed diffuse alveolar damage (DAD). There are hyaline membranes and 
protein-rich fluid in the alveolar spaces, as well as epithelial disruption and infiltration 
of the interstitium and air spaces with neutrophils. Areas of hemorrhage and 
macrophages can also be found in the alveoli. The second stage is so-called 
proliferative stage. In this one hyaline membrane are reorganized and fibrosis begins 
to form, together with the obliteration of pulmonary capillaries and interstitial 
deposition. In the last fibrotic stage, precipitating pulmonary fibrosis appears in a 
subset of patients [4, 18]. 
One of the hallmarks of ALI/ARDS is the accumulation of neutrophils in the 
microvasculature of the lung [19]. Neutrophils and some T-lymphocytes can quickly 
migrate into the inflamed lung parenchyma and contribute to the amplification of the 
inflammation. Neutrophils can generate an array of cytotoxic compounds, which 
include reactive oxygen species, cationic peptides, eicosanoids, and proteolytic 
enzymes. In addition, once activated, neutrophils can release growth factors and 
cytokines (such as tumour necrosis factor-α (TNF-α) and interleukin-1β) that can also 
be secreted from epithelial and endothelial cells. All these factors act to sustain and 
perpetrate the inflammatory response [20].  
The mechanisms of the ARDS/ALI have been and will be intensively studied. So far 
we know that the pathogenesis is mediated by plethora of inflammatory mediators, 
and by recruitment and activation of inflammatory cells through their intricate 
networking and cross talking. In this study, we will raise a new hypothesis that 
platelet activating factor (PAF) regulates edema formation and vascular permeability 
in ARDS/ALI via acid sphingomyelinase (ASM).  
 
1.2.3 Pulmonary edema and acute lung injury 
Pulmonary edema occurs when more fluid is filtered into the lungs more than is 
absorbed. Accumulation of fluid can have serious consequences on lung function, 
because efficient gas exchange cannot occur in fluid-filled alveoli and interstitium. 
Pulmonary edema is mainly caused by either failure of the heart to remove fluid from 
the lung circulation and increase capillary pressure ("cardiogenic edema") or by a 
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direct injury to the lung parenchyma ("non-cardiogenic edema") [21]. Major causes of 
cardiogenic and non-cardiogenic pulmonary edema are listed in table 1. 
 
Table 1: Causes of cardiogenic and non-cardiogenic pulmonary edema [1, 4] 
Cardiogenic edema Non-cardiogenic edema 
Congestive heart failure Inhalation of toxic gases 
Heart attack with left ventricular failure Aspiration, e.g., gastric fluid or in case of 
drowning 
Arrhythmias (tachycardia/fast heartbeat 
or bradycardia/slow heartbeat 
Pulmonary contusion, i.e., high-energy 
trauma 
Hypertensive crisis Multiple blood transfusions 
Pericardial effusion with tamponade infections 
Fluid overload, e.g., from kidney failure 
or intravenous therapy 
Multi-trauma, neurogenic causes 
 Upper airway obstruction 
 Other/unknown 
 
The essential form  that regulate fluid exchange in the lungs can be expressed in the 
Starling equation [22] for the microvascular endothelial barrier:  
 
Jv = Kf [(Pc - Pi) - σ (πc - πi)] 
 
Where [Pc − Pi] − σ[πc − πi] is the net driving force; P and π are the hydrostatic and 
oncotic pressure in the capillary (c) and interstitial (i) compartments; Kf is the filtration 
coefficient, a proportionality constant; Jv is the net fluid movement between the 
endothelial barrier. The Starling equation classifies pulmonary edema into 
“hydrostatic” type and “permeability” type: hydrostatic type caused by hydrostatic 
or/and oncotic pressure gradient and permeability type caused by vascular 
permeability and endothelial barrier dysfunction (see Fig. 2).  
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Fig. 2: Schematic representation of the pulmonary capillary tissue-lymphatic system and 
starling equation [23]. The lymph flow removes the overflow in the system. 
 
The edema caused by altered permeability of pulmonary endothelial barrier for water 
and proteins has been called permeability type edema. This is a characteristic 
hallmark of inflammatory responses and contributes to the morbidity and mortality in 
anaphylaxis, sepsis and acute lung injury (ALI) respectively it’s most severe form, the 
acute respiratory distress syndrome (ARDS) [19, 24].  
Several mechanisms normally protect the lungs against edema such as lymphatic 
pumps, resorption and endothelial as well as epithelial barriers. However, if the 
barriers function is impaired and if protective osmotic pressure differences are lost, 
even normal hydrostatic pressure results in significant fluid and protein influx into 
interstitial and alveolar spaces despite increased the lymph flow. Increased 
permeability edema is often rapid in onset and progression because once injured, the 
barriers offer much less resistance to fluid flow. Subsequently, interstitial edema and 
alveolar filling compromise gas exchange. In acute lung injury, functional residual 
capacity is decreased as a consequence and this loss of respiratory units also 
accounts for virtually all the observed decrease in lung compliance. In addition, 
airflow resistance was increased as a result of decreased lung volume [25-26].  
 
1.3 The regulation of vascular permeability 
The pulmonary endothelium, lining the blood vessels forms a size-selective and 
semi-permeable barrier between the blood plasma and interstitium and controlling the 
passage of macromolecules and fluid between blood and interstitial space [27]. The 
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regulation of vascular permeability by transport of plasma proteins and solutes across 
the endothelium involves two different routes: a) Paracellularly, via inter-endothelial 
junctions. By losing the integrity of endothelial cells and cell junctions, the original 
osmotic gradient can be demolished by protein transport across vascular wall through 
gap formation [28-30]; b) Transcellularly, via transcytosis-mediated vesicular 
transport. Small vesicles can be formed out of membrane invaginations such as 
caveolae and selectively transport macromolecules like albumin across the 
endothelium [30-31].  
1.3.1 Regulation of paracellular permeability 
The paracellular permeability of the endothelial barrier is maintained by the inter-
endothelial junctions. The junction structures connect adjacent endothelial cells and 
regulate the transport of plasma proteins from the vessel lumen to interstitium [4]. 
Three types of inter-endothelial junctions are documented in the endothelium, tight 
junctions (TJs), adherens junctions (AJs) and gap junctions. AJs and TJs function 
promote adhesion of opposing cells in the monolayer and maintain the tightness of 
the endothelial barrier, whereas gap junctions form channels between neighbouring 
cells that pass water, ions, and other small molecules and transmit signals within the 
contiguous monolayer of cells [27]. AJs, composed of the vascular endothelial (VE)-
cadherin complexes with catenins, are dominant and critically contribute to vascular 
paracellular permeability regulation [27]. The general concept is that VE-cadherin-
mediated AJs established prior to TJs in endothelial cell cultures [32] and maintain 
the architectural integrity of endothelium, whereas TJs are secondary and are only in 
the brain microvasculature composing the blood-brain barrier [33-34]. Here, we 
discuss the structure, dynamics, and regulation of the integrity of AJs in relation to 
endothelial barrier function. 
 
1.3.1.1 Endothelial barrier regulation by cadherin and catenin 
In the intracellular junction domain, VE-cadherin interacts with proteins of the 
Armadillo-repeat gene family, β-catenin, plakoglobin (γ-catenin), and p120-catenin. 
The classical junction contains a proximal binding site for p120-catenin, and a distal 
binding site for β-catenin and plakoglobin (see Fig. 3). Both β-catenin and 
plakoglobin are linked to α-catenin, which may further interact with α-actinin and 
vinculin [28]. The binding of β-catenin induces ordering of the last 100 residues of the 
cadherin tail, which is intrinsically highly unstructured [35-36]. Plakoglobin binds the 
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same region of VE-cadherin as β-catenin; however, it displays different dynamics at 
AJs and recruits desmoplakin and vimentin to AJs [37-38]. Recent findings that over 
expression of plakoglobin in human microvascular endothelial cells in culture (HMEC) 
increased endothelial barrier function suggest that plakoglobin contributes to 
strengthening of the endothelial barrier. Inhibition of plakoglobin expression leaded to 
AJs disassembly and endothelial barrier failure under fluid shear stress [37], 
indicating that plakoglobin has a role in stabilizing AJs and endothelial barrier 
function.  
P120-catenin, with β-catenin, also regulates the endothelial barrier at the level of VE-
cadherin expression. Both β-catenin and p120-catenin spatially regulate organization 
of the actin cytoskeleton at the AJs. P120-catenin recruits the p190Rho GTPase-
activating protein (GAP), which stimulates GTP hydrolysis of RhoA [39]. β-Catenin 
associates with IQRas GTPase activating protein 1 (IQGAP1), which is both an 
effector and a regulator of the RhoGTPases Cdc42 and Rac1 [40]. The RhoGTPase 
family members Cdc42, Rac, and RhoA are known to play a critical role in regulating 
permeability of the endothelial barrier under basal conditions and in response to 
external stimuli and will be discussed later in this section. 
The role of α-catenin in the regulation of endothelial AJs has not yet been 
determined. One theory suggests that α-catenin inhibits VE-cadherin recycling at the 
cell surface and supports the functional and structural integrity of the endothelial 
barrier [41-42]. 
 
 
 
Fig. 3: General schematic representation of the composition of adherens junctions (AJs) [30]. 
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1.3.1.2 Endothelial barrier regulation by kinases and phosphatises 
Phosphorylation of VE-cadherin and catenins provides the mechanism for remodeling 
of AJs [43-45]. Kinases and phosphatases modulate the affinities of the proteins 
within the cadherin-catenins complex and thereby determine AJ stability and 
paracellular permeability. The high-affinity interaction between VE-cadherin and β-
catenin can be increased by differential phosphorylation of VE-cadherin or can be 
diminished by phosphorylation of β-catenin [46].  
The cytoplasmic tyrosine kinase c-Src plays a pivotal role in regulating vascular 
endothelial permeability by transducing signals that mediate AJ destabilization and 
acto-myosin contractility (Fig. 4). c-Src activation leads to tyrosine phosphorylation of 
VE-cadherin and β-catenin, resulting in reduction of VE-cadherin binding to p120-
catenin or β-catenin and AJs destabilization [47-48]. c-Src phosphorylation provokes 
the p21-activated kinase (PAK) that mediates phosphorylation of VE-cadherin and 
stimulates a β-arrestin–mediated endocytosis [46]. The activation of protease 
activated receptor-1 (PAR-1) by thrombin mediates the activation of c-Src and leads 
to dissociating Src-homology-2-domain-containing protein tyrosine phosphatase 
(SHP2) from AJs [49-50]. This dissociation provokes tyrosine phosphorylation of β-, 
γ-, and p120-catenins, and AJ destabilization [50]. In contrast, the cytosolic C-
terminal Src kinase Csk binds to the phosphorylated Tyr685 of VE-cadherin and 
protects it from Src-mediated phosphorylation [51].  
 
 
 
Fig. 4: c-Src-mediated signalling in paracellular permeability regulation [30]. MLCK: myosin 
light chain kinase; PAK: p21-activated kinase; SHP2: Src-homology-2-domain-containing 
protein tyrosine phosphatises. Further details please see in text 1.3.1.2. 
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c-Src can also regulate paracellular permeability by inducing tyrosine phosphorylation 
of endothelial-specific myosin light chain kinase (MLCK) and resulting in a 2-3 fold 
increase in kinase activity [52]. MLCK dependent phosphorylation of the regulatory 
myosin light chain facilitates acto-myosin contraction [53]. Thus, c-Src mediated 
MLCK activation provides an additional mechanism for regulating the reorganization 
of the actin cytoskeleton by developing an endothelial cell shape change and 
formation of inter-endothelial gaps with level of Ca2+ not increased. 
1.3.1.3 Endothelial barrier regulation by calcium and ion channels 
Ca2+ (calcium ion) is a ubiquitous messenger regulating multiple processes including 
paracellular endothelial permeability and vascular endothelial homeostasis [54]. The 
basal cytosolic Ca2+ concentration in endothelial cells is about 100 nM. However 
extracellular stimuli like thrombin, histamine or bradykinin can significantly increase 
the cytosolic Ca2+ concentration and activate phospholipase C (PLC). As seen in Fig. 
5, panel a, activated PLC further hydrolyzes phosphotidyl inositol bisphosphate 
(PIP2) into inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 stimulates Ca2+ 
release from the IP3 sensitive endoplasmic reticulum (ER) Ca2+ store, which in turn 
activates signalling molecules that mediate Ca2+ entry through store operated 
channel (SOC) which might contain canonical transient receptor potential channels 
(TRPC1, -4, -5). Alternatively, DAG can stimulate receptor operated channel (ROC) 
mediated Ca2+ entry independently of Ca2+ store depletion. TRPC3 and -6 are 
believed to participate in the ROC mediated Ca2+ influx [55]. Spontaneously, changes 
in ER Ca2+ content are “sensed” by the stromal-interacting molecule (STIM1, STIM2) 
which relay this signal to the Ca2+ channel (Orai1) [56-58]. These increases in 
cytosolic Ca2+ concentration are short-lived, as excess Ca2+ is rapidly removed via 
the plasma membrane Ca2+-ATPase (PMCA) [59-60] and sarco/endoplasmic 
reticulum Ca2+-ATPase (SERCA) [60-61]. 
Protein kinase Cα (PKCα) is a member of a serine and threonine-specific protein 
kinase family that is activated by Ca2+ and the second messenger DAG [62]. 
Although PKCα does not control basal permeability, it is a central regulator of the 
endothelial permeability response to multiple mediators [63]. As seen Fig. 1.3.3, 
Panel b PKCα selectively promotes phosphorylation of p120-catenin at Ser879, 
leading to p120-catenin dissociation from VE-cadherin and AJ destabilization. PKCα 
also modulates RhoA GTPase activation by phosphorylation of the upstream RhoA 
regulators [64-65]. RhoA activation is accompanied by Ca2+/calmodulin-dependent 
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activation of MLCK and MLC phosphorylation leading to actino-myosin contraction 
and loss of endothelial barrier protection [66-67]. 
In this regard, PKCα cooperates with MLCK to elicit a coordinated spatial activation 
of RhoA and reorganization of the actin cytoskeleton, resulting in endothelial 
increased permeability. In addition, besides the direct effect of PKCα on the 
cytoskeleton and AJs, PKCα also regulates endothelial barrier functions indirectly by 
mediating the activation of other signalling pathways. For instance, PKCα induced 
the phosphorylation of eNOS and increased NO production [68], suggesting a 
coordinate role of PKCα and eNOS in the mechanism of endothelial barrier 
hyperpermeability. 
 
 
 
Fig. 5: Calcium signalling and paracellular permeability. Panel a shows the SOC and ROC 
operating Ca2+ influx. Panel b shows the Ca2+ regulated paracellular permeability. GPCR: G 
protein receptors; PLC: phospholipase C; DAG: diacylglycerol; SOC: store operated 
channels; ROC: receptor operated channel; PMCA: plasma membrane Ca2+-ATPase; STIM: 
Stromal-Interacting Molecule; SERCA: sarco/endoplasmic reticulum Ca2+-ATPase. TRPC: 
canonical transient receptor potential channels. Further details please see in text 1.3.1.3. 
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1.3.1.4 Endothelial barrier regulation by RhoGTPase signalling 
The RhoGTPase family members Cdc42, Rac, and RhoA play a critical role in 
regulating permeability of the endothelial barrier function especially in response to 
external stimuli. The stabilization of AJs is associated with activities of Rac1 and 
Cdc42, although some RhoA activity is required to maintain a subminimal amount of 
MLC phosphorylation, which is critical for the formation of cortical actin bundles at the 
sites of cell-cell adhesions [69]. Generally, Rac1 and Cdc42 operate the spatial 
control of filopodial and lamellipodial activity of endothelial protrusions, whereas 
RhoA facilitates the organization of actin stress fibers [70]. As seen in Fig. 6, 
RhoGTPase controls paracellular permeability by multiple mechanisms that enable 
activation of Cdc42 and Rac1 and inhibition of RhoA. 
 
 
 
Fig. 6: RhoGTPase signalling in paracellular permeability regulation. IQGAP: IQRas 
GTPase activating protein; ROCK: Rho-associated protein kinase; MLCP: myosin 
light chain phosphatises. Further details please see in text 1.3.1.4. 
 
p190RhoGAP plays a central role in inhibiting RhoA at the sites of cell-cell 
adhesions, and its function depends on the interaction with p120-catenin, which 
provides a platform for the physical interaction between p190RhoGAP and RhoA, 
enabling the spatial inhibition of RhoA in AJs [39]. p190RhoGAP activity is positively 
regulated by c-Src-mediated phosphorylation [71-72]. In contrast, Rho kinase 
(ROCK)-mediated phosphorylation negatively regulates p190RhoGAP activity [73]. 
p190RhoGAP inhibits RhoA, and RhoA, in turn, is able to facilitate phosphorylation-
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induced inhibition of myosin light chain phosphatise (MLCP) by activating Rho kinase 
(ROCK) [74-75]. The facilitation of MLCP leads to phosphorylation of MLC with 
subsequence acto-myosin contraction and endothelial leakage [66-67]. 
p190RhoGAP mediated inhibition of RhoA required Rac1 activity [39], which is 
regulated by Tiam-1 [76]. Tiam-1 regulates Rac1 and cooperates with p190RhoGAP 
to inhibit RhoA and stabilize the AJs [77]. Vice versa, recruitment of Tiam-1 to the AJ 
complex might also induce p190RhoGAP translocation and thereby sustained 
inhibition of RhoA. In addition, the activities of IQGAP1 and Cdc42 are also important 
in regulating AJ integrity [76]. IQGAP1 stabilizes Cdc42 and Rac1 in their active 
GTP-bound forms [40], binds to β-catenin and can promote Rac1-mediated activation 
of p190RhoGAP [78]. Further proof is that depletion of IQGAP1 destabilizes AJs, 
whereas overexpression of IQGAP1 restores them in Rac1-deficient cells [79]. 
 
1.3.2 Regulation of transcellular permeability 
The transcellular pathway has been defined as the receptor-mediated transport of 
albumin from the vessel lumen to the interstitial space [80]. Transport occurs by 
means of transcytosis, an energy-dependent trafficking of vesicles though the 
endothelial cells [81]. The paracellular pathway allows free permeation of fluid and 
solutes from blood plasma to the interstitial space but restricts the passage of 
albumin and other large plasma proteins [82-83]. The difference in protein 
concentration between plasma and interstitial space maintains the trans-endothelial 
oncotic pressure, a key driving force that regulates tissue fluid homeostasis [84-85]. 
However, the abnormal transport of albumin from plasma to the interstitium via trans-
endothelial manner can increase the water content in the interstitial space and 
thereby disturb the fluid balance across the endothelium leading to protein rich 
edema [85]. 
Transcytosis requires a complex series of events involved caveolae and its structural 
protein caveolin-1. Caveolae and caveolin will be discussed later in detail in the 
section 1.6 “lipidraft and caveolae”. In the initial step of transcytosis, caveolar fission 
is regulated by activation of dynamin at the caveolar neck. The following scission and 
release of caveolar vesicle is associated with GTPase RhoG and GTP hydrolysis of 
dynamin [80, 86-88]. Cav-1 is a structural protein of caveolae. Caveolin-1 deficient 
mice demonstrated increased permeability due to albumin leakage in endothelia of 
                                                                                                                                                                  Introduction 
 16
small veins and capillaries [89-90], suggesting a transcellular pathways in regulating 
tissue fluid balance. 
As seen in Fig. 7, gp60 interacting with caveolin-1 leads to vesicle fission and 
albumin transport [91-93]. Src-kinase family member c-Src and heterotrimeric G 
proteins Gαi and Gαq are also recruited into caveolae [94]. Interaction of gp60 with 
Cav-1 triggers activation of c-Src and Gαi dissociation from Gβγ [91, 93]. Activation 
of c-Src and Gαi sequentially leads to tyrosine phosphorylation of Cav-1 and dynamin 
[91, 93, 95-96], following recruitment of dynamin into caveolae and eventually 
formation of the dynamin ring on caveolar necks [93, 97-98]. 
 
 
Fig. 7: Signalling mechanisms of caveolae-mediated albumin transport [30, 99]. 
 
Normally, albumin transcytosis is a constitutive process at part of the normal 
maintenance of fluid balance across the endothelium. The accumulation of protein-
rich interstitial fluid associated with up-regulated transport of albumin only happens 
under tissue injury and leads to protein rich edema [27, 100].  
For instance, activation of neutrophils and their sequestration in pulmonary 
microvessels lead to activation of albumin transcytosis and increased water content 
in the alveolar space [101], and this process is Cav-1-dependent, as neutrophil 
sequestration in lungs of caveolin-1 deficient mice did not induce hyperpermeability 
to albumin [101]. 
Caveolae not only participate in albumin trafficking and transcellular permeability, 
they also compartmentalize signalling molecules within caveolae microdomains and 
facilitate dynamic interactions among signalling cascades. Cav-1 serves as a scaffold 
that interacts with and modulates activity of binding partners [27, 80]. Here, in this 
thesis we will describe that caveolin-1 negatively regulate eNOS activity in response 
to PAF. 
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1.3.3 Mediators regulating endothelial permeability 
Sphingosine-1-phosphate (S1P) is a bioactive lipid mediator produced by the 
breakdown of the membrane phospholipid sphingomyelin [102-103]. S1P mediates 
endothelial barrier function through activation of the five G protein–coupled receptors 
(S1P1-S1P5), and different S1P receptor subtypes may regulate vascular permeability 
antagonistically: endothelial barrier is enhanced by S1P1 but impaired by S1P2 and 
S1P3 [104-105]. S1P1 coupling to G proteins induces signalling toward Rac1 
activation and reorganization of the actin cytoskeleton into cortical bundles in concert 
with cortactin, α-actinin 1 and 4, paxillin and the GPCR kinase–interacting proteins 
[106-107]. S1P signalling also increases the abundance of VE-cadherin at the cell 
surface and induces AJ enhancement [108] (for details, please see “sphingolipids 
dection”). 
Platelet-activating factor (PAF), a phospholipid produced by a variety of cell types 
including endothelial cells, plays an important role in regulating vascular homeostasis 
[109]. PAF activates a G protein–coupled receptor, PAF-R, localized at the cell 
surface and in intracellular compartments [109]. The binding of PAF to the cell 
surface receptor induces PLCs activation and leads to reorganization of actin 
cytoskeleton associated vascular permeability [110-111]. PAF response on vascular 
barrier homeostasis are also associated with PAF-R-mediated transcriptional 
regulation of NO production and Ca2+ influx [109] (For the details please seen 
following section of “platelet activating factor”). 
Thrombin, a procoagulant serine protease, is a pro-inflammatory mediator, which 
induces intravascular thrombosis and formation of fibrin clots [112]. Thrombin 
mediates a transient increase in paracellular permeability. Signals through Gαq and 
Gα12/13 proteins, lead to activation of PLCβ and sequentially to increased 
intracellular Ca2+ concentration [74].  
Vascular endothelial growth factor (VEGF) is a proangiogenic cytokine that is 
essential for developmental and pathological angiogenesis [113-114]. Paracellular 
permeability induced by the release of VEGF is mediated through activation of its 
high-affinity receptor tyrosine kinase VEGFR2 [115-116]. The VEGF-VEGFR2 
signalling induces an increased endothelial permeability via Src-mediated signalling 
of VE-cadherin internalization in a relative long time course comparing with PAF 
thrombin, and activation of PLC-γ that mediates an increase in intracellular Ca2+ 
concentration [117]. 
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Fibroblast growth factor (FGF) is an angiogenic cytokine that plays an important role 
in the maintenance of endothelial barrier function through the regulation of AJ 
integrity [118]. FGF binds to a high-affinity cell surface tyrosine kinase receptor 
FGFR. Its interaction with p120-catenin leads to stabilization of VE-cadherin and 
enhancement of endothelial barrier [118].  
Bradykinin is an inflammatory mediator generated by cleavaging kinin peptides at the 
sites of tissue injury [119]. The permeability response to bradykinin is mediated 
through activation of the B2 receptor that is ubiquitously expressed in resting 
endothelial cells [120]. The signal is coupled by Gαq, resulting in an increased 
concentration of intracellular Ca2+ and subsequently in activation of endothelial nitric 
oxide synthase (eNOS) [121]. 
In summary, Many signalling pathways of catenins, kinases [122-123], myosin light 
chains (MLC) and Rho have been identified [63, 124-127] in endothelial permeability 
regulation, but the exact mechanisms of endothelial barrier failure still requires further 
study. Of note, there are only few mediators can alter pulmonary vascular 
permeability in minutes or even seconds, and PAF is one of them. We will discuss in 
the rest of thesis, new hypotheses and regulatory pathways of increased endothelial 
permeability in the pulmonary vasculature induced by PAF, in particular with respect 
to eNOS and TRPC channels. 
 
1.4 Platelet activating factor 
Platelet-activating factor, also known as a PAF, PAF-acether or AGEPC (acetyl-
glyceryl-ether-phosphorylcholine) is a potent phospholipid activator and mediator of 
many leukocyte functions, including platelet aggregation, inflammation, and 
anaphylaxis. It is produced in response to specific stimuli by a variety of cell types, 
including neutrophils, basophils, platelets, and endothelial cells.  
This phospholipid was originally shown to induce aggregation of blood platelets 
released from basophils stimulated with immunoglobulin E by J. Benveniste in 1972 
[128-129], and its structure was elucidated as 1-alkyl-2-acetyl-sn-glycero-3-
phosphocholine by Constantinos A. Demopoulos in 1979 [130] (see Fig. 8).  
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1.4.1 Chemistry and Biology of PAF 
PAF is an unusual lipid, as lipids with alkyl groups only in position sn-1 are not 
common in animals. As seen in Fig. 8, the alkyl group is connected by an ether 
linkage at the C1 carbon to a C16 or C18 chain; the acyl group at the C2 carbon is an 
acetate unit whose short length increases the solubility of PAF, allowing it to act as a 
soluble signal messenger; The C3 has a phosphocholine head group, just like 
standard phosphatidylcholine. 
 
  
Fig. 8: Structure of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (PAF). 
 
PAF was the first phospholipid known to have messenger functions, and to signal 
though specific receptors rather than to act though its physico-chemical effects on the 
plasma membrane or other cell membranes. There is a strict structural requirement 
for binding to its unique single G-protein coupled receptor (PAF-R), which is 
expressed by numerous cells including all those of the innate immune system. There 
is a relatively high specificity for the ether bond in position sn-1 of PAF in comparison 
to the 1-acyl analogue, together with considerable specificity for a short acyl chain in 
position sn-2 and for the phosphorylcholine head group [128, 131-133]. 
PAF is synthesised by a variety of cells, but especially those involved in host 
defence, such as platelets, endothelial cells, neutrophils, monocytes and 
macrophages. PAF is synthesised continuously by cells, but at low level, controlled 
by the activity of PAF acetyl hydrolases (see below). However, it is produced in much 
greater quantities by inflammatory cells when receiving cell-specific stimuli.  When 
the cells are subjected to acute inflammatory stimulation, the activated enzymes 
produce PAF in appreciable amounts, a distinct membrane-bound acetyltransferase 
(LPCAT2) transfers an acetyl residue from acetyl-CoA to 1-alkyl-sn-glycero-3-
phosphocholine (lyso-PAF), generated by the action of phospholipase A2 on 
phosphatidylcholine [134-136]. Alternatively, PAF also can be produced by 
acetylation of 1-alkyl-sn-glycero-3-phosphate, which is converted to 1-alkyl-2-
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acetylglycerol and thence to PAF.  But this ‘de novo’ pathway is believed to be non-
inflammatory [137-138]. 
Initially, PAF was shown to trigger aggregation of platelets at concentrations as low 
as 10-11 M, and it induced a hypertensive response at very low levels as well. Recent 
work has been concerned with the function of PAF as a mediator of inflammation, 
and its role in the immune response. For example, it has a number of pro-
inflammatory properties, and it has been implicated in the pathogenesis of a number 
of disease states, ranging from allergic reactions to stroke, myocardial infarction, 
colitis and multiple sclerosis. For example, In asthma, platelet-activating factor is able 
to act directly as a chemotactic factor and indirectly by stimulating the release of 
other inflammatory agents. Administration of PAF can produce many of the 
symptoms observed in asthma, partly via the formation of leukotrienes as secondary 
mediators. 
By binding to its specific receptor, PAF activates the cytoplasmic phospholipase A2 
(PLA2) and phospholipase C (PLC), and tyrosine phosphorylation of various proteins. 
The result of the latter is an increase in intracellular Ca2+; activation of protein kinase 
C and mitogen activated protein kinase (MAPK) [139-140]. The G protein dependent 
phosphatidylcholine specific phospholipase C mediates the following hydrolysis of 
phosphatidylcholine and leads to generation of inositol 1,4,5-trisphosphate (IP3) and 
diacylglycerol (DAG). IP3 increases intracellular Ca2+ via IP3 receptors (IP3R) as well 
as DAG mediate protein kinase C (PKC) activation [138, 141]. 
 
1.4.2 PAF in vascular permeability and edema formation 
PAF plays a central role in many pulmonary disorders. In the lungs, PAF contracts 
airway and vascular smooth muscle and causes vascular gaps in capillaries, venules 
and veins [142-147]. All these actions take place in minutes and are all believed to be 
associated with lipid mediators and lipid modifying enzymes (see Fig. 9).  
Particularly, cyclooxygenase and lipoxygenase trigger bronchial and vascular smooth 
muscle contractions via their products thromboxane and leukotrienes C4 and D4 [148-
149]. Rho kinase appears to regulate both thromboxane release and thromboxane 
effects on smooth muscle contraction [150]. These evidences are mostly based on 
pharmacological inhibitors of leukotrienes or thromboxane that prevented the 
vascular and brocho-constriction in isolated perfused rat lung [151].  Cyclooxygenase 
can also regulate the edema formation by prostaglandin E2 (PGE2) and activation of 
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EP3 receptor [152]: In isolated perfused rat lung it was shown that PAF stimulates 
PGE2 release and perfusion with neutralizing anti-PGE2 antibodies attenuated the 
PAF-induced edema formation [152]; Sulprostone, an EP1/3-receptor agonist induced 
the edema in isolated perfused rat lung but not the EP2-receptor agonist butaprost  
[152].  
 
 
 
Fig. 9: Overview on the mechanisms of PAF induced bronchocontriction, vasoconstriction 
and edema formation [148-149]. LTC4: leukotrienes C4; LTD4: leukotrienes D4; PGE2: 
Prostaglandin E2; TXA2: thromboxane A2; NO: nitric oxide. Further details please see in 
text 1.4.2. 
 
There is another pathway which is not well studied so far is believed to be involved 
with activation of acid sphingomyelinase (ASM) and ceramide production [111]. PAF 
can rapidly increase intracellular ceramide level in several cell types [111, 153-154], 
and this pro-inflammatory related ceramide is produced by ASM [111]. Ceramide can 
induce edema formation both by lung perfusion and by airway instillation [111, 155]; 
and the ceramide specific antibodies can attenuate the PAF-induced edema 
formation in perfused lung [111]. ASM Inhibition pharmacologically by D609 or 
genetically by Smpd1 depletion did also prevent the PAF-induced edema formation 
[111]. 
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It was the major aim of this study to reveal the role of the ASM-ceramide pathway in 
regulation of pulmonary vascular permeability in response to PAF. 
 
1.5 Sphingolipids 
The sphingolipids comprise a complex range of lipids in which fatty acids are linked 
via amide bonds to a long-chain base or sphingoid. The term “sphingo-” was first 
coined by J.L.W. Thudichum in 1884 because the enigmatic nature of these 
molecules reminded him of the sphinx. Sphingolipids are extremely versatile 
molecules regulating many physiological processes such as apoptosis, innate and 
acquired immunity, vascular permeability, smooth muscle tone, and they contribute to 
various pathological conditions [111, 156-157]. 
 
1.5.1 General comments of sphingolipids 
Sphingosine is the fundamental structural group to sphingolipids. Its phosphorylation 
generates sphingosine-1-phosphate (S1P) and its acylation generates ceramide. 
Sphingomyelins have a phosphorylcholine or phosphoroethanolamine molecule with 
an ester linkage to the 1-hydroxy group of a ceramide. Figure. 10 shows the 
metabolism of all these sphingolipids. Sphingolipids are synthesized in a pathway 
that begins in the ER and is completed in the Golgi apparatus, but most of these 
lipids are enriched in the plasma membrane and in endosomes where they perform 
most of their functions [158]. Sphingolipids are virtually absent from mitochondria and 
the ER, but constitute a 20-35 molar fraction of plasma membrane lipids [159]. 
Sphingolipid metabolites, such as ceramide and sphingosine-1-phosphate, have 
been shown to play an important role in the signalling cascades involved in 
apoptosis, proliferation, stress responses and vascular permeability [105, 111, 156, 
160].  
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Fig. 10: Overview of sphingolipid metabolism [156]. 
 
Ceramide consists of a long-chain sphingoid base linked to a fatty acid via an amide 
bond. The level of ceramide in tissues in low, but they can still exert important and 
various biological effects. Ceramide is formed as the key intermediate in the 
biosynthesis of all the complex sphingolipids, in which the terminal primary hydroxyl 
group is linked to carbohydrate, phosphate, etc. Unlike the sphingoid precursors, 
ceramide is not soluble in water and is located in membranes where it participates in 
raft formation [161-162]. 
Besides the de novo synthesis, ceramide is also produced during the catabolism of 
other complex sphingolipids, for example by the activation of the sphingomyelinases 
(acid-/neutral sphingomyelinase) on sphingomyelin or ceramide synthase on 
sphingosine [163-164]. Many agonists including chemotherapeutic agents, tumor 
necrosis factor (TNF), PAF, 1,25-dihydroxy-vitamin D3, endotoxin, interleukins, nerve 
growth factor (NGF), irradiation and heat shock stimulate hydrolysis of sphingomyelin 
to produce ceramide [111, 154, 165-167].  
Ceramides are minor component of membranes in general, but their physical 
properties ensure that they are concentrated preferentially into lateral liquid-ordered 
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microdomains (a form of 'lipid raft' termed to ‘ceramide-rich platforms’) [168]. 
Ceramide is generated within these rafts by the action of acid sphingomyelinase that 
causes small rafts to merge into larger units then modifying the membrane structure 
and property [161-162, 168-169]. Specific receptor molecules and signalling proteins 
cluster within such platform excluding potential inhibitory signals, while initiating and 
greatly amplifying primary signals [156]. 
It is believed that ceramide-rich platforms amplify both receptor- and stress-mediated 
signalling events and thence may influence various disease states. Assuming wide 
range of biological functions in cellular signalling, ceramide is known as a pro-
apoptotic molecule and to respond to many forms of cellular stress. Ceramide has 
also been implicated in the activation of various protein kinase cascades: Ceramide 
was to shown to interact with ceramide-activated protein phosphatase and ceramide-
activated protein kinases to regulate glycogen synthesis, insulin resistance in 
response to apoptotic stimuli [170-173]. In addition, ceramide can influence the 
permeability of cell membranes via interaction with ion channels and by triggering 
pore formation [174-175].  
Sphingosine-1-phosphate (S1P), a zwitterionic lysophospholipid, is an important 
cellular metabolite, derived from sphingosine. It is an inter-mediator in the irreversible 
degradation of sphingolipids, and also has important signalling functions. 
Like its precursors, sphingosine-1-phosphate is a potent messenger molecule which 
is recognized as an ubiquitous regulator of cell proliferation and survival, 
angiogenesis and endothelial barrier functions, cytoskeletal organization, cellular 
Ca2+ homeostasis, cell-cell contacts, and adhesion [176-178]. Sphingosine-1-
phosphate exerts many of its extra-cellular effects through acting as a ligand for 
specific G protein-coupled receptors on cell surfaces, designated S1P1 to S1P5. In 
mammals, S1P1, S1P2, and S1P3 are found in all tissues, whereas S1P4 is restricted 
to lymphoid tissues and lung and S1P5 to brain and skin [178]. Different S1P receptor 
subtypes may act antagonistically: especially in the lung, endothelial barrier is 
enhanced by S1P1 but impaired by S1P2 and S1P3 (see table 2) chemotaxis is 
stimulated by S1P1 but inhibited by S1P2 [104-105].  
There is accumulating evidence that sphingosine-1-phosphate and its receptors 
regulate heart rate, blood flow in the coronary artery and the mechanisms have to be 
identified [179-180]. It also has been suggested that S1P, together with other 
lysolipids such as sphingosylphosphorylcholine and lysosulfatide, are responsible for 
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the potent anti-atherogenic and anti-inflammatory signalling molecule nitric oxide 
(NO) in the vascular endothelium [181]. In addition sphingosine-1-phosphate has a 
pro-inflammatory function that responds to certain cytokines and bacterial 
lipopolysaccharides (LPS) and induces up-regulation of the enzyme cyclooxygenase-
2 (COX-2) and thence produces the prostaglandin PGE2 [182-184].  
 
Table 2: Pulmonary response of sphingolipids 
Outcome Sphingolipids Receptors References 
▲Endothelial barrier S1P S1P1 [105, 185] 
▼Endothelial barrier S1P 
Ceramide 
S1P2, S1P3 [186-187] 
[111] 
▼Epithelial barrier S1P S1P3 [188-189] 
▲Apoptosis Ceramide  [190-192] 
▲Survival S1P S1P1 [190, 193-194] 
Airway contraction S1P S1P2, S1P3 [195] 
Emphysema Ceramide  [192] 
Mast cell activation S1P S1P1 [196] 
 
1.5.2 Regulation of pulmonary disease by sphingolipids 
1.5.2.1 Sphingolipds and vascular permeability 
Vascular permeability is regulated by sphingolipids in numerous ways. S1P enhances 
endothelial barrier function, and this barrier stabilizing function appears to be mainly 
mediated by S1P1 receptors and involves activation of Rac GTPase dependent 
cytoskeletal reorganization and focal adhesion assembly [185]. S1P was also shown 
to protect against lipopolysaccharides (LPS) induced pulmonary edema and ALI 
[197-198]. On the other hand, S1P2 causes Rho-kinase–dependent inhibition of Rac 
and impairing of adherence junctions [186], and S1P3 is known to increase epithelial 
[188-189] and endothelial permeability [187].  
S1P1 coupling to Gi induces signalling associated Rac1 activation and reorganization 
of the actin cytoskeleton. Cortactin, α-actinin, paxillin, focal adhesion kinase (FAK), 
and the GPCR kinase–interacting proteins GIT1 and GIT2 are also required [106-
107]. S1P-induced activation of Rac1 is mediated by Tiam-1 which is the Rac1 
guanine nucleotide exchange factor. Recruitment of Tiam-1 into caveolae or cell-cell 
space is the precondition for spatial modulation of the S1P-mediated Rac1 activation 
and depends on phosphoinositide 3-kinase (PI3K) activity [199]. Recruitment of 
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Tiam-1 to the caveolae facilitates its stabilization and abundance by inhibiting Tiam-1 
degradation [200]. Tiam-1/Rac1 signalling cooperates and provokes p190RhoGAP 
whose main function is inhibiting RhoA [77]. RhoA facilitates the inhibition of myosin 
light chain phosphatise (MLCP) by activating Rho kinase (ROCK) [74-75]. The 
inhibition of MLCP leads to phosphorylation of MLC and induces acto-myosin 
contraction, which leads to endothelial barrier dysfunction [66-67, 201]. S1P 
signalling also increases the abundance of VE-cadherin at the cell surface and 
induces AJ assembly [108]. 
Interestingly, activation of S1P2 causes Rho-kinase dependent inhibition of Rac and 
impairs adherence junctions [186], and signalling though S1P3 receptor is known to 
increase epithelial [188-189] and endothelial permeability [187]. This bidirectional 
phenomenon may be explained by coupling to different G proteins thus provoking 
different signalling pathways (see Fig. 11). The enhancement of endothelial barrier 
and activated Rac/Tiam is only regulated by S1P1 coupling to Gi.  Activation of S1P2 
on endothelial cell inhibits their migration and increases vascular permeability, most 
likely through mechanisms involving Rho-dependent inhibition of Rac and stimulation 
of the 3′-specific phosphoinositide phosphatase PTEN [202-203]. This S1P2 activated 
Rac inhibition requires G12/13 and Gq. The G12/13 and Gq induces Rho activation by 
direct physical and functional interaction between Gα12/13/ Gαq and Rho-guanine 
nucleotide exchange factors (Rho-GEFs) [204]. S1P3 mediates vasoconstriction 
through Gq coupled Ca2+ mobilization and G12/13 regulated Rho dependent myosin 
light chain phosphatase inhibition in vascular smooth muscle cells (VSMCs) [205-
206]. In addition, S1P3 can also activate eNOS and provoke NO production in 
vascular endothelial cells through Gi-and Akt-mediated phosphorylation of eNOS in 
concert with a Gq-mediated, Ca2+/calmodulin-dependent activation [207]. 
 
                                                                                                                                                                  Introduction 
 27
 
Fig. 11: signalling pathways of S1P receptors and G proteins 
 
Ceramide is also involved in the regulation of vascular permeability. PAF can 
stimulate the ceramide production rapidly by ASM activation [111, 154]. In the PAF-
induced edema, ASM inhibition or anti-ceramide antibody perfusion can mitigate the 
edema formation in isolated perfused lung model [111, 142]. Ceramide can induce 
edema formation by lung perfusion [111] or instillation in rat airways [155]. In cultured 
human pulmonary microvascular endothelial cells, ceramide also increased vascular 
permeability [208].  In addition, it seems that endothelial cell apoptosis does not 
contribute to vascular permeability regulation [142, 208].  
 
1.5.2.2 Ceramide and pulmonary infections 
Ceramide-enriched micro domains seem to act as a platform that permits the spatial 
and temporal organization of receptors and signalling molecules [161-162, 168-169]. 
Thus, it was shown that several receptors and signalling molecules including CD95 
[209-211], CD40 [212], FcgRII [213], CD14 [214], CFTR [215], caspase 8 [216] and 
platelet activating factor [111], were reported to trigger the formation of such 
ceramide-enriched membrane platforms.  
Ceramide-enriched membrane platforms are thought to be one important regulatory 
factor in pulmonary infections. Pseudomonas. aeruginosa infection is one well 
studied case. 40% of deaths in patients with ventilator-associated pneumonia are 
caused by P. aeruginosa [217]. Infection triggers rapid forms of acid 
sphingomyelinase transport to the extracellular leaflet of the cell membrane where 
the ceramide-enriched membrane platforms [218]. It was shown that CD95 receptor 
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and cystic fibrosis transmembrane conductance regulator (CFTR) molecules cluster 
within this platform upon infection [218-219]. CD95 was previously shown to mediate 
apoptosis of cells infected with P. aeruginosa and CFTR was known as a receptor for 
P. aeruginosa, mediating internalization of the bacteria [220-221]. Additional 
evidence is that ceramide-enriched platform destruction prevented NF-КB nuclear 
translocation in respiratory epithelial cells and cellular apoptosis [215, 218].  
 
1.5.2.3 Ceramide and cystic fibrosis             
Mutations in CFTR cause cystic fibrosis which is the most common autosomal 
recessive disorder [222]. Cystic fibrosis is characterized by chronic lung 
inflammation, and frequent and chronic infections of the lung with P. aeruginosa, as 
well as S. aureus, Burkholderia cepacia and Haemophilus influenzae. It was 
unknown how CFTR deficiency results in increased pulmonary inflammation and the 
high susceptibility to bacterial infections until a new explanation came up recently 
implicating that ceramide and acid sphingomyelinase in that process. CFTR 
deficiency results in an increase in pH that may affect enzymatic activity of acid 
sphingomyelinase and acid ceramidase [223]. pH up to 6.0 almost inhibited acid 
ceramidase whereas acid sphingomyelinase activity was only decreased by 30–40% 
[223-224]. The accumulated ceramide can further trigger chronic pulmonary 
inflammation, death of respiratory epithelial cells, and deposition of DNA in bronchi. 
Of note, inhibition of ASM in CFTR deficient mice can prevent pulmonary infections of 
P. aeruginosa.  
 
1.5.2.4 Sphingosine-1-phosphate and allergic disorders 
Asthma is characterized by bronchial epithelium abnormalities in function and 
structure, accumulation of inflammatory cells in the bronchial mucosa and airway 
tissue structure remodelling. Many mediators have been identified that play 
significant roles in the initiation and progression of the disease, among them, 
sphingosine-1-phosphate (S1P) appears to be an active metabolite that regulates 
allergic responses in asthma and anaphylaxis. The first finding that S1P may play a 
role in asthma was that S1P levels were elevated in the bronchoalveolar lavage 
(BAL) fluid of asthmatics after antigen challenge, and this elevated S1P level was 
associated with eosinophil numbers, a hallmark of asthma [225].  
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Sphingosine-1-phosphate and mast cell function in the allergic response 
Mast cells play central roles in immediate-type and inflammatory allergic reactions 
that can result in asthma. Cross-linking of the high affinity immunoglobulin E receptor 
FcεRI on master cells induces activation of sphingosine kinases, production of S1P 
and subsequent activation of the S1P1 and S1P2 receptors [226]. Activation of S1P2 
is required for mast cell degranulation while S1P1 activation is important for their 
migration to sites of inflammation. S1P Binding to S1P1 induces cytoskeletal 
rearrangements and triggers mast cell migration towards an antigen gradient [226], 
by which low antigen concentrations could attract master cell to the action site via 
S1P1. On the other hand, S1P2 mediates mast cells activation and promotes 
degranulation [226]. Secretion of S1P by mast cells also provokes inflammation by 
activating and recruiting other immune cells like eosinophils [227] and Th2 
lymphocytes [228]. 
Sphingosine kinases phosphorylate sphingosine to form S1P. Two mammalian 
isoforms of sphingosine kinases have been identified, named SphK1 and SphK2. 
Furthermore, SphK1 and SphK2 display different catalytic properties, subcellular 
locations and substrate specificity [176]. Crosslinking of the FcεRI activates SphK1 
and SphK2, increases S1P production and decreases sphingosine [226, 229]. The 
majority of studies of S1P in mast cells have been focused on SphK1; it was believed 
that down-regulation of SphK1 but not SphK2 inhibited Ca2+ mobilization, 
degranulation and migration of mast cells induced by antigen [226, 229-230]. 
However, recent studies have shown that both SphK1 and SphK2 were activated 
upon FcεRI engagement in murine and immature human mast cells, and this required 
Fyn kinase in bone marrow-derived mast cells [231]. Exogenous addition of S1P can 
restore the migration and degranulation in Fyn deficient animals [231]. Furthermore, it 
was recently shown that depletion of Sphk2, but not Sphk1, suppressed FcεRI-
mediated generation of S1P, as well as Ca2+ influx, PKC activation, degranulation 
and cytokine secretion [232].  
Sphingosine-1-phosphate and airway smooth muscle cells and airway remodeling 
Another defining feature of an asthmatic attack is the contraction of airway smooth 
muscle. S1P stimulates contraction of human airway smooth muscles in a Rho-
dependent manner associated with activation of S1P2 and S1P3 [195]. S1P induced a 
dose-dependent contraction in isolated bronchi from sensitized mice [233]. S1P also 
caused airway hyperresponsiveness in the ovalbumin-sensitized mouse model of 
asthma, and both S1P2 and S1P3 receptors expression. In addition, SphK1 and 
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SphK2 activity were up-regulated in the ovalbumin-sensitized mouse asthma model 
[233]. Inhibition of SphK impaired airway hyperresponsiveness in a murine asthma 
model [234].  
The regulation of S1P in airway remodelling has also been characterized. First, S1P 
promoted the proliferation of both human airway smooth muscle cells [225] and 
fibroblasts [235-236]. Furthermore, S1P produced by SphK1 has recently been 
shown to be involved in fibroblast differentiation into myofibroblasts, which was 
believed to be relevant to lamina reticularis thickening [237]. Additionally, it was 
shown that transforming growth factor (TGF-β) stimulates SphK1, which in turn 
released S1P that activates S1P2 and S1P3, leading to α-smooth muscle actin 
expression in lung fibroblasts which is hallmark of their differentiation into 
myofibroblasts [237]. 
 
1.5.2.5 Ceramide and pulmonary emphysema 
Emphysema is a chronic, obstructive pulmonary disease primarily caused by 
cigarette smoking. It is characterized by a destructive and permanent enlargement of 
distal airspaces and alveolar walls, ultimately leading to impaired oxygenation. 
Historically, the pathogenesis of emphysema has been linked to chronic lung 
inflammation, and more recently it has been recognized that alveolar cell apoptosis is 
a crucial step in the pathogenesis of this disease [238]. There is evidence showing 
that ceramide is a crucial mediator of alveolar destruction in emphysema. In the 
model of vascular endothelial growth factor blockade, formation of ceramide 
predominantly increased in alveolar cells, which was mediated by an increased 
activity of the ceramide synthase pathway and a feed forward activation of the ASM 
[192]. Increased ceramide was critical to trigger alveolar cell death, oxidative stress 
[239] and inhibition of ceramide, via anti-ceramide antibodies or inhibition of enzymes 
controlling de novo ceramide synthesis prevented this phenomenon. It seems that 
emphysema develops partially as the results of ceramide mediated oxidative stress 
and apoptosis of alveolar endothelial and epithelial cells [192, 239], then endothelial 
ceramide may be a novel target to prevent or treat emphysema and chronic 
obstructive pulmonary disease (COPD). 
 
1.5.2.6 Niemann-pick disease 
Sphingomyelinases are characterized by their pH optimum, with acid, neutral and 
alkaline sphingomyelinase identified [240-242]. Although all these three enzymes 
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have general mechanisms for ceramide generation and cell signalling, the majority of 
studies have focused specifically on the contributions of acid sphngomyelinase 
(ASM). Niemann-pick disease (NPD, type A, B) is a rare genetic disorder that is 
caused by ASM deficiency. Both forms of this disorder are inherited as recessive 
traits, and both are due to mutations in the SMPD1 gene [243-244]. Type A NPD is 
the infantile form, which is characterized by neurological deficits, enlarged livers and 
spleens, pulmonary infections and death by age 2–3 [156]. In contrast, type B NPD is 
the later onset form, in which patients exhibit little or no neurological symptoms but 
may have severe and progressive visceral organ abnormalities, including 
hepatosplenomegaly, pulmonary insufficiency, and cardiovascular disease [245]. 
Many of the clinical findings in NPD are likely related to lipid storage in lysosomes 
and endosomes, and recent data have also revealed the important role of ASM in cell 
membrane formation and function. Impaired pulmonary function is also a major 
clinical finding in patients with type B NPD [246]. A similar outcome was observed in 
ASM knockout mice [247].  
 
1.6 Lipid rafts and caveolae 
1.6.1 History and biology 
According to the fluid mosaic model of S. J. Singer and Garth Nicolson in 1972, the 
biological membranes can be considered as a two-dimensional liquid where all lipid 
and protein molecules can diffuse more or less easily [248]. Furthermore, the plasma 
membrane contains different structures or domains that can be classified as a) 
protein-protein complexes; b) lipid rafts, c) pickets and fences formed by the actin-
based cytoskeleton; and d) large stable structures, such as synapses or 
desmosomes [248-249].  
The original concept of lipid “rafts” was used as an explanation for the transport of 
cholesterol from the Golgi network to the plasma membrane. The idea was more 
formally developed in 1997 by Simons and Ikonen [250]. Eventually lipid rafts were 
defined as "small (10-200nm), heterogeneous, highly dynamic, sterol- and 
sphingolipid-enriched domains that compartmentalize cellular processes, and small 
rafts can sometimes be stabilized to form larger platforms. Two types of lipid rafts 
have been proposed: planar lipid rafts (also referred to as non-caveolar or glycolipid 
rafts) and caveolae. Planar rafts are defined as being continuous with the plane of 
the plasma membrane (not invaginated). Caveolae, on the other hand, are flask 
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shaped invaginations of the plasma membrane that contain caveolin proteins and are 
the most readily-observed structures in lipid rafts [251-252]. 
Caveolae (Latin for little caves, singular: caveola) were first identified by electron 
microscopic examination by Yamada in 1950s [251], this “cave-like” domain is the 
flask-shaped structures enriched in proteins as well as lipids such as cholesterol and 
sphingolipids and have several functions in signal transduction [253]. Caveolae are 
also believed to play a role in endocytosis, transcytosis, and the uptake of pathogenic 
bacteria and certain viruses [254-255]. Since then, caveolae have been identified in a 
wide variety of tissues and cell types. Particularly, caveolae have been well described 
in adipocytes, fibroblasts where they are extremely abundant, endothelial cells, type I 
pneumocytes, striated and smooth muscle cells. Additionally, ultra-structural analysis 
of adipocytes has shown that as much as 20% of the total plasma membrane is 
occupied by caveolae [253, 256]. 
Formation and maintenance of caveolae is primarily dependent on the protein 
caveolin which has a cytoplasmic C-terminus and a cytoplasmic N-terminus, linked 
together by a hydrophobic hairpin and inserted into the membrane. It has estimated 
144 molecules of caveolin are present in a single caveolar structure [257], and the 
relative amount of cholesterol in caveolae is much more. Some glycosphingolipids 
and sphingomyelin are also enriched in caveolae relatively to the plasma membrane. 
Interestingly, the density of lipids was found to be higher in the caveolae than in the 
plasma membrane fraction from which the caveolae were isolated [258]. In summary, 
caveolae represent a specialized, morphologically distinct sphingolipid-cholesterol 
microdomain, which is stabilized by the unique caveolin protein. 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                                  Introduction 
 33
 
 
Fig. 12: Caveolae and caveolin. Panel a shows the electron micrograph in adipocytes; panel 
b indicates how caveolin is inserted to form caveolae membrane [99]. 
 
1.6.2 Caveolins 
Caveolins are a family of integral membrane proteins which are the principal and 
particular components of caveolae membranes. This 21~24 kDa protein together with 
cholesterol and sphingolipids form the major structural components of caveolae 
[249]. Caveolins also act as scaffolding proteins to compartmentalize and 
concentrate signalling molecules within caveolar [99]. Various types of signalling 
molecules, including G-protein subunits, receptor and non-receptor tyrosine kinases, 
eNOS, and small GTPases can bind caveolin through its 'caveolin-scaffolding 
domain' and this binding leads to inhibition of their activity [259]. 
The caveolin gene family has three members in vertebrates: CAV-1, CAV-2, and 
CAV-3, respectively coding for the proteins caveolin-1, caveolin-2 and caveolin-3 
[260]. All three members are membrane proteins with similar structure. CAV-1 the 
first gene which was discovered, is derived by alternative translational initiation 
and/or mRNA splicing of two different isoforms: caveolin-1α consisting of residues 1-
178 and the caveolin-1β containing residues 32-178, resulting in a protein of ~ 3 kDa 
smaller size [261]. Caveolin-2 has three identified isoforms: caveolin-2α, -2β and -2γ, 
and they are closely related to caveolin-1 as they colocalize and heterooligomerize 
together with caveolin-1 [259, 262]. Caveolin-1 is most prominently expressed in 
endothelial, fibrous and adipose tissue, and it seems to be co-expressed with 
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caveolin-2. The expression of caveolin-3 is restricted to muscle cell type (cardiac, 
skeletal, smooth muscle) [263-265]. Interestingly, ablation of Cav-1 and Cav-3 
caused caveolae absence, but loss of Cav-2 has no apparent effect on caveolae 
formation [266-268]. 
The so called “caveolin scaffolding domain” (CSD) is a region spanning 20 residues 
in the caveolin sequence (mapping to residues 81-101 in the human caveolin-1 
sequence) [94]. Using a glutathione S-transferase (GST)-CSD fusion protein as a bait 
to select peptide ligands from a bacteriophage display library, Lisanti and colleagues 
indentified a “caveolin binding motif” (CBM) that appeared to be presented in  many 
proteins located in caveolae (ΦΧΧΧΧΦΧΧ or ΦΧΦΧΧΧΧΦ, where Φ is an aromatic 
amino acid) [269]. Different signalling proteins but containing CBM can all bind 
caveolins and their activity are spontaneously inhibited  [259]. 
 
1.6.3 Biological function role of caveolae 
With so many different types of molecules, proteins and receptors located in 
caveolae (see table 3), it is evidential that they should play an important function role 
in many cellular processes especially as macromolecules transportation [83, 270-
271], nitric oxide (NO) generation [272-273], ion-channel regulation [274-275], 
angiogenesis regulation [276], shear stress and regulation of vascular permeability 
[266, 277]. 
 
Table 3: Proteins and receptors located in caveolae 
Proteins Functions References 
Caveolin Signalling and major structure [249, 259, 278] 
Flotillin Signalling and structure [279-280] 
Actin Cell motility [278, 281] 
SNAP Vesicular transportation [282] 
G proteins G protein related receptor activation [278, 283] 
IP3 receptor  Calcium flux [284-285] 
M6P receptor Receptor for mannose-6-phosphate [286] 
Tyosine kinase Signalling and transcription  [278, 287] 
Ser/Thr kinase Signalling and phosphorylation [81, 278, 287-288] 
eNOS NO production and signalling [259, 289] 
nNOS  Neuronal NO production and signalling [290] 
COX Metabolism and signalling [291] 
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1.6.3.1 Caveolae, caveolins and endocytic processes 
The observation that caveolae exist as invaginations of the plasma membrane, as 
completely enclosed vesicles, and as aggregates of several vesicles may suggest 
that this structures are involved in the endocytosis of macromolecules [292].  
Surprisingly, It was revealed that cells predominantly used caveolae for the selective 
uptake of molecules as full size proteins [164-165], viruses [293] and even entire 
bacteria [294].  
The classical endocytosis is associated with clathrin coated vesicles, but it seems 
that certain receptors and extracellular macromolecules are exclusively transported 
via caveolae rather than clathrin vesicles [99]. This alternative caveolar pathway was 
first recognised by the observation that cholera toxin was preferentially bound and 
internalized via caveolae (see Fig. 13). Budded caveolae, here known as endocytic 
caveolar carriers carrying cholera toxin binding subunit (CTxB), can fuse into the 
caveosome, or with the early endosome or be recycled back to the plasma 
membrane for reuse. This process is regulated by dynamin, protein kinases or 
tyrosine kinases [295-297]. 
 
 
Fig. 13: Caveolae endocytosis [99]. CTxB: cholera toxin binding subunit. Further details 
please see in text 1.6.3.1. 
 
In endothelial cells, the endocytosed caveolae seem to migrate from the luminal side 
to the abluminal side, thereby transferring specific serum molecules to the underlying 
tissue and this process is referred to transcytosis [292, 298]. The first direct evidence 
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supporting an involvement of caveolin-1 and caveolae in transcytosis was shown by 
perfusion with gold-labelled albumin in wild type and caveolin-1 deficient mouse 
lungs. The wild type endothelial cells associated with gold-labelled albumin, 
internalized and transferred it to the sub-endothelial space through caveolae, but no 
uptake or transfer was observed in caveolin-1 deficient mice [89]. Transcytosis can 
be both constitutive (fluid-phase transport) or receptor-mediated (the molecule 
transported requires the presence of its cognate receptor in caveolae) and many 
types of macromolecules such as albumin, insulin, Low-density lipoprotein (LDL) 
have been associated with caveolae-mediated transcytosis [89, 270, 299]. The 
regulation of endothelial permeability by transcytosis and caveolin has been 
introduced in the “vascular permeability regulation” section. In addition, caveolae 
have also been implicated in a unique form of solute uptake referred to as 
potocytosis in which cells can transport small molecules (< 1 kDa), without 
endocytotic vesicles, in caveolae to internal endosomal/lysosomal compartments 
[300]. 
 
1.6.3.2 Caveolae, caveolins and cholesterol homeostasis 
Caveolae are highly enriched in cholesterol relatively to the plasma membrane. 
Depletion of cholesterol led to loss of identifiable caveolae [301] and caveolin 
deficient mice showed less free cholesterol and cholesterol export [302]. From these 
observations, it has been suggested that caveolae and caveolins are involved in 
maintaining intracellular cholesterol balance. Cholesterol from de novo production or 
extracellular uptake can be transported from endoplasmic reticulum to membrane 
caveolae with assistance of caveolin [303-304]. Upon delivery, the cholesterol could  
a) remain in caveolae as a functional structure, b) be siphoned into the bulk plasma 
membrane, c) be effluxed to serum cholesterol-transporting units like high density 
lipoproteins (HDL) [303, 305]. In essence, the caveolins deliver intracellular 
cholesterol to a "relay station" wherein the overall fate of cholesterol is determined 
[99]. 
 
1.6.3.3 Caveolae, caveolins and signal transduction 
Caveolae are highly enriched in numerous membrane bound proteins, especially 
signalling proteins with lipid modified groups (H-ras, src-family tyrosine kinases, 
heterotrimeric G-proteins, eNOS, etc) [258, 306] . It appears that caveolins can bind 
and functionally regulate (mostly inhibit) several of these caveolae-localized 
                                                                                                                                                                  Introduction 
 37
molecules [94, 257, 289, 307-308]. Caveolin scaffolding domain (CSD) mediates this 
functional binding process. In addition, caveolae have also been implicated in the 
regulation of ion channels and calcium recruitment [309-310]. 
 
1.6.3.4 The endothelial nitric oxide synthase, Caveolae and vascular permeability 
Nitric oxide (NO) is a multifaceted molecule which plays key roles in many biological 
situations [311]. Endothelial nitric oxide synthase (eNOS) is the major NOS isoform 
responsible for cardiovascular homeostasis, vessel tonicity and permeability. eNOS 
is a calmodulin activated enzyme which consists of an oxygenase and a reductase 
domain containing binding sites for a variety of cofactors that promote electron 
transfer from one domain to the other, leading ultimately to the conversion of L-
arginine to citrulline and NO [312]. 
eNOS is found enriched in caveolae where it interacts with caveolins directly. The 
interaction between eNOS and caveolins has been well documented. Transgenic 
overexpression of Cav-1 inhibited eNOS activation without increasing caveola 
formation [313-314]. Further in a mouse inflammation model, delivery of the caveolin-
1 scaffolding domain reduced the vascular permeability response and tissue edema 
formation by sequestering eNOS [315]. The interaction between eNOS and caveolins 
involves three sites: the oxygenase and reductase domain of eNOS and CSD domain 
of caveolin. eNOS enzyme activity is dependent on the calmodulin binding, the 
activation of which requires an increase in intracellular [Ca2+]. Binding of eNOS to 
caveolins holds it in the inactive state and away from Ca2+. When intracellular Ca2+ 
increases, eNOS complexes with Ca2+/calmodulin dissociates from caveolin; thereby 
it increase eNOS activity and NO production. It appears that calmodulin acts as direct 
allosteric competitor promoting the disruption of the heteromeric complex formed 
between eNOS and caveolins in a Ca2+ dependent manner [272, 313, 316]. 
Accordingly, peptides corresponding to the CSD domain were shown to interact 
directly with the enzyme and to markedly inhibit eNOS activity [316]. In addition, 
eNOS is also regulated by phosporylation mediated by the Ser/Thr kinase Akt [317]. 
Phosphorylation could bidirectionally increase and decrease eNOS activity: 
phosphorylation at serine (Ser1179) increased eNOS activity and sensitivity to 
Ca2+/CaM, whereas phosphorylation at threonine (Thr497) negatively regulated eNOS 
activity [317-318].  
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NO is a ubiquitous cell-permeable intracellular messenger that plays an important 
role in the regulation of vascular endothelial barrier homeostasis. It is believed that 
decreased NO biogenesis contributes to chronic hypertensive diseases, whereas 
increased synthesis contributes to inflammation and vascular disorders [319-320]. 
There are findings that increased NO production might lead to increased transcytosis 
and vascular permeability in mice challenged with the bacterial endotoxin LPS [100]. 
Consistent with this outcome, sequestering of eNOS by conjugated caveolin-1 
scaffold domain (CSD) peptide, which decreases NO synthesis, concomitantly 
reduced the vascular permeability response in a mouse model of inflammation [315]. 
In contrast, in PAF-treated human mesangial cells in culture, rapid increased 
permeability was accompanied with the cessation of endothelial NO synthesis [321]. 
These findings may seem conflicting, but we believe the more rational explanation is 
that both too much and too little NO can increase vascular permeability, so that NO 
synthase inhibitors can either attenuate or aggravate pulmonary hyperpermeability, 
and that also depends on the time and measurements. This discussion will be 
continued discussion section (5.2.2 regulation of vascular permeability by nitric 
oxide).  
 
1.6.3.5 Ca2+, TRPC channels and caveolae 
Ca2+ signalling in endothelial cells plays a key role in maintaining the barrier integrity. 
In the section “endothelial barrier regulation of Ca2+ and ion channel” we have 
generally addressed the mechanisms of Ca2+ influx and vascular permeability 
regulation. Signalling from inflammatory mediators like thrombin, bradykinin and PAF 
might activate canonical transient receptor potential (TRPC) channels mediated by  
diacylglycerol (DAG) and inositol trisphosphate (IP3). Ca2+ signalling induces actin 
polymerization and myosin light chain (MLC) phosphorylation leading in turn to the 
generation of contractile forces through actin myosin cross-bridging [322]. The 
generated contractile force results in cell retraction and increased endothelial 
permeability [322-323].  
Several channels, receptors and mediators have been identified to be associated 
with endothelial barrier function and caveolae such as store/receptor operated 
channel (SOC/ROC) [275], canonical transient receptor potential (TRPC) [324-325] 
and the inositol 1,4,5-trisphosphate receptor (IP3R) [285, 326]. These channels or 
receptors are reported to be involved in regulation of endothelial barrier function and 
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permeability [54, 323]. It is important to note that both IP3R and Ca2+-ATPase have 
been described in the plasma membrane and especially in caveolae [81, 284-285]. In 
many reports it is also described that IP3R and TRPC channels are found in a multi-
complex with caveolin-1 in membrane microdomains [327-329]. 
TRPC channels form a subfamily of channels in human most closely related to 
drosophila TRP channels. These channels are permeable to cations, with a 
selectivity of Ca2+ over sodium variable among the different members. The seven 
TRPC channels can be divided into four subgroups based on their structure and 
functional similarities: a) TRPC1; b) TRPC2; c) TRPC3, TRPC6, and TRPC7; and d) 
TRPC4 and TRPC5 [330-331]. The fluorescence resonance energy transfer (FRET) 
and co-immunoprecipitation studies [332] imply that TRPC2 does not interact with 
any other TRPC proteins [333]; TRPC1 has the ability to form channel complexes 
together with TRPC4 and TRPC5 and these three channels are sometimes 
considered to represent a store operated calcium channel (SOC) [323]; All other 
TRPCs assemble exclusively into homo- or heterotetramers working as (receptor 
operated calcium channel) ROC, sharing a high degree of amino acid identity (70–
80%) and functional, pharmacological, and regulatory similarities (e.g.TRPC3/6/7) 
[323].  
In this thesis, we have focused on the role of the signals regulating the entry of Ca2+ 
through the TRPC channels and the response to endothelial barrier integrity as well 
as vascular permeability. 
 
1.7 The isolated perfused lung model 
In the studies of whole animals, there is an elaborate exchange of information and 
cross-talk between the lung and other organs [334]. It is necessary to eliminate or 
simplify the influence from other organs to study lung functions independent from the 
systemic complexity. One physiologically relevant model that can be used to study 
lung functions especially the edema formation is the isolated perfused rat lung (IPL) 
[335-336]. It is a distinct advantaged model  that studies are performed in an isolated 
intact organ that stands in between experiments in vivo with whole animals and in 
vitro with cultured cells [334]. This model allows examining physiological responses 
of the lung which in four categories: respiratory mechanics, vessel mechanics, gas 
exchange and edema formation. Since the study can be performed in an intact lung, 
the physiological parameters can be determined with established cell-to-cell contacts 
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and native intracellular matrixes [334].in our own hands, some substances known to 
induce edema in vivo or in isolated perfused lung like PAF have no effect on 
permeability in endothelial cell monolayer experiments [274, 337]. Unlike the whole 
animal experiments, parameters like ventilation / perfusion pressure, perfusion flow 
velocity, perfusate composition can be controlled and most of the information of lung 
physiology like airway and vascular resistance, tidal volume, pulmonary compliance 
and lung weight can be continuously monitored. It is also possible to distinguish 
hydrostatic edema from permeability edema, by using constant pressure perfusion. In 
addition, luminal plasmalemma of the lung endothelium can be isolated and purified 
by a particular perfuse protocol using silica beads [284].  
Real-time fluorescence imaging (RFI), combining microscopic imaging of the isolated 
perfused lung, have enabled the investigation of lung cellular and molecular 
responses in situ [338]. This method provides an opportunity for obtaining optical 
data specifically from intact epithelial and endothelial cells of alveoli and 
microvessels. By designed fluorescent indicators, it allows us to detect the diatomic 
free-radical NO and cytosolic Ca2+ levels in individual endothelial cells in intact 
capillaries [339-340]. In this thesis, our cooperating group of Prof. W. Kuelber would 
perform the Real-time fluorescence imaging to examine the endothelial NO and 
cytosolic Ca2+ level in isolated perfused rat/mouse lungs. 
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2 The aim of the study 
Vascular permeability is a hallmark of pulmonary inflammation. In the lungs increased 
vascular permeability leads to Acute Lung Injury (ALI) and the Acute Respiratory 
Distress Syndrome (ARDS), clinical conditions for which mortality remains high. One 
important mediator that plays a critical role in many experimental models of ALI is the 
platelet-activating factor (PAF). PAF increases vascular permeability by activation of 
two lipid modifying enzymes: cyclooxygenase leading to production of PGE2 followed 
by activation of EP3 receptors and acid sphingomyelinase (ASM) leading to formation 
of ceramide. The mechanisms by which ASM-metabolites regulate vascular 
permeability were unknown and were subject of the present studies. 
The major aim of this work was to investigate the mechanisms by which ASM 
regulates the PAF-induced increased pulmonary endothelial permeability. 
Particularly, we focused on the role of NO synthesis and Ca2+ influx in response to 
PAF. Since caveolae are particularly rich in sphingolipids, we asked whether PAF 
acts in the realm of caveolae and which role they play in PAF-induced edema 
formation. Therefore, it was another goal of this thesis to establish a method for the 
isolation of caveolae from intact endothelial cells of isolated perfused rat lungs and to 
characterise these caveolae in PAF-treated lungs. 
This work was supported by DFG grants Uh 88/8-1 and Ku 1218/5-1 within the DFG 
Priority Programme 1267 “Sphingolipids – Signal and Disease”. In this cooperation, in 
Aachen I have performed the experiments on edema formation in isolated perfused 
rat lungs, the measurement of acid sphingomyelinase activity, the purification of 
caveolae from the pulmonary endothelium from intact lungs and the characterization 
by immunoblotting. Our cooperating group of Prof. W. Kuelber in Berlin has 
performed in situ fluorescence microscopy for imaging of endothelial calcium 
transients and NO production. 
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3 Material and Methods 
3.1 Materials 
3.1.1 Animals 
Male Sprague-Dawley rats (350 to 450 g for in situ fluorescence imaging), female 
C57 mice (18-22g for isolated perfused lung) and female Wistar rats (weight 220 to 
250g for isolated perfused lung) were kept under controlled conditions (22°C, 55% 
humidity and 12 h day/night rhythm) and a standard laboratory chow (V1534-000 sniff 
R/M; Ssniff Spezialdäten GmbH, Soest, Germany) and water ad libitum.  
In addition, the TRPC6 knockout mice were from cooperating group of Prof. 
Alexander Dietrich, Institute of pharmacology, Philipps-Universität Marburg and Prof. 
Thomas Gudermann, Institute of pharmacology and Toxicology, Ludwig-Maximilians-
Universität München. ASM knockout mice were from cooperating group of Prof. 
Dieter AdamA, institute for immunology, Christian-Albrechts-Universität Kiel. 
All animals received care in accordance with the Guide for the Care and Use of 
Laboratory Animals. The study was approved by the local animal care and use 
committee of the local government authorities. Pentobarbital sodium (Nacoren, 400 
µL/kg) was purchased from the Wirtschaftsgenossenschaft Deutscher Tieräzte 
(Hannover, Germany). 
 
3.1.2 Substances and chemicals  
 
Table 5: Overview of inhibitors, substances and suppliers 
Substances Concentration Supplier 
Platelet-activating factor 
(PAF,1-O-alkyl-2-acetyl snglycero-3-
phosphocholine) 
 
5 nmol/IPL 
~50 nM 
Sigma (Taufkirchen, Europe) 
[N-methyl-14C] Sphingomyelin 
 
472.7 nM GE Healthcare 
D609 (Tricyclodecan-9-ylxanthate 
potassium Salt) 
 
300 µM Sigma (Taufkirchen, Europe) 
Imipramine (hydrochloride) 
 
10 µM Sigma (Taufkirchen, Europe) 
L-NAME (L-N-Nitroarginine 
methylester (hydrochloride) ) 
250 µM Sigma (Taufkirchen, Europe) 
SKF-96365, (hydrochloride) 
 
30 µM Sigma (Taufkirchen, Europe) 
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PAPA NONOate 
 
100 µM AXXORA Germany 
ARC39 1 µM Generous gift from Prof. 
Christoph Arenz Humboldt 
university, Berlin 
 
Aluminium chlorohydroxide 
 
105 g/L PFATZ & BAUER Inc, USA 
Nycodenz 
 
70%-55% Axis-Shield PoC AS, Norway 
Dexamethasone 
 
10 µM Sigma (Taufkirchen, Europe) 
Silica beads (diameter of 5 µm) 10% Bangs Laboratories Inc, 
USA 
 
Ruthenium red 1 µM Fluka (Germany, Europe) 
 
3.1.3 Other Buffers and chemical solutions 
TBS: Tris-Buffered Saline buffer contains 10 mM Tris, 150 mM NaCl (pH 7.6). 
TBS-T: Tris-Buffered Saline buffer contains 10 mM Tris, 150 mM NaCl and 0.1% 
Tween 20. 
MBS: MES-Buffered Saline solution contains 125 nM NaCl and 20 mM MES (pH 6). 
HBS: HEPES-Buffered Sucrose solution contains 0.25 mM Sucrose, 25 mM HEPES 
(Sigma, Taufkirchen, Germany) and 2mM PEFA-Bloc as a protease inhibitor (Roche, 
USA). 
Krebs-Henseleit buffer: 2% bovine serum albumin (Serva, Heidelberg, Germany) 
solution contains 0.1% glucose and 0.3% HEPES. 
NO-sensitive fluorescence dye 4-amino-5-methylamino-2’,7’-difluorofluorescein 
diacetate (DAF-FM) and the NO donor S-nitroso-N-acetylpenicillamine (SNAP) were 
obtained from Molecular Probes (Eugene, OR, USA). 
Electrophoresis Buffer: Tris-Glycine SDS Buffer. 
Immunoblotting Buffer: Tris-Glycine Buffer contains 20% methanol. 
Destilled water. 
 
 
 
 
 
 
                                                                                                                                                  Material and methods 
 44
3.1.4 Antibodies 
 
Table 6: Overview of antibodies for Immunoblotting 
Primary Antibodies Dilution Secondary 
antibodies 
Supplier 
Goat anti rat ACE 1:1000 Alexa-Fluor 800nm Donkey 
anti goat 
Santa Cruz 
Biotechnology, USA 
Mouse anti rat Caveolin-1 1:1500 Alexa-Fluor 680 nm Goat 
anti mouse 
BD Transduction 
Laboratories, Europe 
Mouse anti rat Flotillin-1 1:500 Alexa-Fluor 680 nm Goat 
anti mouse 
BD Transduction 
Laboratories, Europe 
Goat anti rat LAMP-1 1:1000 Alexa-Fluor 800nm Donkey 
anti goat 
Santa Cruz 
Biotechnology, USA 
Rabbit anti rat eNOS 1:1000 Alexa-Fluor 700 nm Goat 
anti rabbit 
BD Transduction 
Laboratories, Europe 
Mouse anti rat PeNOS 1:1000 Alexa-Fluor 680 nm Goat 
anti mouse 
BD Transduction 
Laboratories, Europe 
Mouse anti rat TRPC-6 1:500 Alexa-Fluor 680 nm Goat 
anti mouse 
Generous gift from 
Prof. Veit Flockerzi 
University  Saarlandes, 
Germany 
 
Secondary antibodies, Alexa-fluorochrome labelled were obtained from Moleculare 
Probes (Eugene, USA). It was used in a dilution of 1:10000~1:15000. 
 
3.1.5 Equipment 
Isolated perfused rat lung from Hugo Sachs Electronics (March-Hugstetten, 
Germany). 
LE-80K Ultracentrifuge, SW55Ti rotor and SW28 rotor from Beckmann (Palo Alto, 
USA). 
Polytron PT 1200 from Kinematica AG (Littau Luzern, Switzerland). 
Hoefer SE600 Electrophoresis system (Germany). 
TE 77 PWR blotting system from Amersham biosciences (GE, USA). 
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3.2 Methods 
3.2.1 Isolated perfused lung 
To study the edema formation and the role of membrane microdomains (caveolae) in 
pulmonary response to PAF, we used the isolated perfused rat lung preparation. 
 
3.2.1.1 Preparation of isolated, ventilated and perfused rat lungs 
Rat lungs were prepared and perfused essentially as described [334-335]. Briefly, 
lungs were perfused through the pulmonary artery at a constant hydrostatic pressure 
(12 cm H2O) with Krebs-Henseleit-buffer. Perfusate buffer contained 2% albumin, 
0.1% glucose and 0.3% HEPES. Edema formation was assessed by continuously 
measuring the weight gain of the lung. 
 
3.2.1.2 Experimental design of the perfused lung studies 
After preparation and 40 minutes perfusion, 5 nmol PAF (dissolved in ethanol) was 
injected as a bolus directly into the perfusate. Imipramine (10 µM), ARC39 (1 µM), L-
NAME (100 µM), dexamethasone (10 µM) and PAPAnonoate (100 µM) were 
prepared in perfusate buffer and were added into the buffer reservoir 10 min prior to 
PAF administration. In ASM sole perfusion, ASM (1 U/mL in perfuse buffer) was 
continuously infused for 30 min into venular capillaries of isolated lungs via a venous 
microcatheter 
 
3.2.1.3 Lung filtration coefficient measurement 
The lung filtration coefficient (Kf) was measured as described [341]. Briefly, the lung 
filtration coefficient was determined by suddenly raising or lowering the perfusion 
pressure by 5 cm H2O and analysing the resulting weight transients by bi-exponential 
regression. The measurement was done before and after the stimulation of PAF or 
PAF plus inhibitors and the differences of Kf in their two measurements was 
calculated. 
 
3.2.1.4 Coating of silica-beads with aluminium hydroxide (chlorohydrol) 
The coating of silica particles was accomplished essentially as described by 
Jacobson et al [284]. Silica beads, with a diameter of 0.5 µm, were coated with 
aluminium hydroxide to generate a positively loaded surface. 10.5 g chlorohydrol was 
mixed with 90 mL distilled water and blended with 1.5 g beads for 2 min in a high 
speed blender. The mixture was then stirred manually and incubated in a water bath 
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at 80°C for 30 min. Silica beads were chilled down to room temperature (RT) for 16h. 
After cooling the pH was adjusted to pH 5.0 with 1 M NaOH. Beads were incubated 
again for 24h and the pH was once more adjusted to pH 5.0 with 1M NaOH. Silica 
bead suspensions were stored at 4°C. Before the coated beads were used for 
perfusion, the bead solution was diluted to 10% silica with attachment buffer (140 mM 
sorbitol, 20 mM MES) and centrifuged for 5 min at 800 x g. The beads cake was 
washed and resuspended in MBS-buffer and centrifuged for 5 min at 800 x g for 
three times. The washed beads were then used for purification of caveolae from 
intact pulmonary endothelial cells. 
 
3.2.1.5 Perfusion of rat lung with cationic colloidal silica beads 
Silica perfusion was accomplished by a method, described by Schnitzer et al [284]. 
The method was slightly modified. After a 40 minutes perfusion, 5 nmol PAF (final 
concentration 50 nM) was injected as a bolus directly into the perfusate. After 10 
minutes the flow rate was reduced from 20 mL/min to 2-3 mL/min and the lungs were 
perfused with the following solutions: MBS buffer for 90 sec at room temperature and 
1 % colloidal silica beads in MBS buffer (10°C); MBS buffer for 90 sec (10°C), to 
clear free silica beads from the lungs; 1% sodium polyacrylate in MBS buffer for 90 
sec (10°C), to crosslink and shield membrane-bound silica; and finally with 8-10 mL 
HBS buffer (10°C). 
 
3.2.1.6 Purification of endothelial cell membrane 
After silica perfusion lungs were removed and immersed in cold HBS, the lung was 
minced with a cutter to small pieces on ice and then transferred to 10 mL HEPES 
buffer. Minced lung pieces were homogenized on ice using a Polytron PT 1200 and a 
Teflon pestleglass homogenizer (15 strokes) with a high speed motor running at 425 
x g. After filtration through a 0.65 μm and 0.45 μm Nytex net (GE Osmononics Inc, 
Minnetoka, USA) the homogenate was mixed with an equal volume of 1.02 g/mL 
Nycodenz containing 20 mM KCl and then layered over 0.5-0.7 g/mL Nycodenz 
containing 60 mM sucrose in a centrifuge tube. After centrifugation (72128 x g, 30 
minutes, 4°C in a Beckman SW 28 rotor) the floating tissue debris were removed and 
the pellet, which contained the silica-coated endothelial membranes fragments was 
resuspended with 1 mL MBS buffer. Subsequently, the suspension was 
homogenized by Polytron PT 1200. 
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3.2.1.7 Isolation of caveolae from silica-coated endothelial cell membrane 
The caveolae from purified pulmonary endothelial cell membrane were isolated as 
described by Melkonian et al [342], and Arni et al [343]. The pellet containing the 
silica-coated endothelial membranes fragments was resuspended with 1 mL MBS (20 
mM MES, 150 mM NaCl, pH 6.0) and 10% Triton-X-100 (final concentration of 1%) 
for 60 minutes at 4°C. After incubation the suspension was homogenized and the 
homogenate was mixed with 80% sucrose to achieve a 40% membrane-sucrose-
solutions. A 30-5% sucrose gradient was layered over the samples in a Beckman 
SW55Ti rotor tube and centrifuged at 4°C overnight at 109368 x g for 16-18 h. 
Fractions of 3x150 µL were removed from the top to the bottom and collected as six 
membrane fractions (0 and A-E); the pellet was dissolved in 150 µL MBS (pellet-
fraction, P). Figure 14 summarized the procedure for isolation of caveolae from intact 
pulmonary endothelial cells as described above. 
 
 
 
 
Fig. 14: Experimental procedure for isolation of the endothelial caveolae from isolated 
perfused rat lungs. 
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3.2.2 Determination of protein concentration by bicinchoninic acid protein 
assay (BCA assay) 
The protein concentrations of all membrane fraction samples were determined with a 
BCA assay (Pierce, Rockford, USA). A volume of 25 µL from each sample was mixed 
with 200 μL BCA working solution. The working solution contain BCA-reagent A (1 
mg sodium bicinchoninate, 2 mg sodium carbonate, 0.16 mg sodium tartrate, 0.4 mg 
NaOH, and 0.95 mg sodium bicarbonate) and 2 volumes BCA-reagent B (0.4 mg 
cupric sulfate (5 x hydrated) in 10 mL distilled water). Samples were incubated 30 
minutes at 37°C. The amount of protein present in the solution was quantified by 
measuring the optical intensity at 562 nm that was referenced by linear regression to 
protein solutions with known concentrations. 
 
3.2.3 Sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
Equal amounts of protein (5 µg) were separated by SDS-poly acrylamide gel 
electrophoresis (12% for caveolin-1, 8% for eNOS). Samples were added to the 
stacking gel and run by 100 V for 40 minutes. To separate the proteins in the 
resolving gel the voltage was increased to 200 V for 100 min. The SDS-PAGE was 
performed of room temperature in 1 x electrophoresis buffer solution. 
 
3.2.4 Immunoblotting 
After SDS-PAGE separation, proteins were transferred to nitrocellulose membranes 
(Schleicher&Schuell, Marienfeld, Germany). The protein transfer on nitrocellulose 
membranes was performed with the TE 77 PWR blotting system at 0.8 mA/cm² for 75 
minutes. The blots were washed with 1 x TBS-T buffer (1 min) and blocked by Roti® 
Block (Roth, Karlsruhe, Germany) for 1 h at RT. The nitrocellulose membranes were 
incubated overnight at 4°C with different primary antibodies. After washing, 
nitrocellulose membranes were incubated with a secondary infrared fluorochrome 
labelled antibody for 1 h at RT and protein bands were detected at 680 or 800nm 
wavelength with the Odyssey® Infrared Imaging system (LI-COR, Bad Homburg, 
Germany). All specific protein bands were quantified with the Odyssey® imaging 
software (LI-COR, Bad Homburg, Germany). 
All gels were loaded with exactly the same amount of protein and all membranes 
were scanned with exactly the same settings (e.g. background correction, contrast, 
channel settings, etc.). Fig. 15 shows the samples from a control and a PAF lung that 
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were analyzed on the same gel and that similarly shows increased Cav-1 in the 
caveolar fractions from PAF treated lungs.  
 
 
Fig. 15: Pooled immunoblots showing Cav-1 distributions from untreated control condition 
and PAF-treated (10 min after bolus injection of 5 nmol PAF) isolated perfused rat lungs from 
fraction A–E in same gel.  
 
3.2.5 Acid sphingomyelinase activity 
Acid sphingomyelinase (ASM) activity was determined by using 14C-labelled 
sphingomyelin [344]. For all samples, 10 µg protein diluted to 10 µL was incubated at 
37°C for 2h with 40 µL substrate (73 nmol 14C-labelled sphingomyelin + 400 nmol 
sphingomyelin). Lipids were separated by chloroform/methanol extraction, 4 mL 
scintillation liquid was added and radioactivity counted in a ß-counter. 
 
3.2.6 Electron microscopy 
Lungs were fixed by perfusion with 250 mL Caco-buffer (100 mM Na-cacodylate, 100 
mM NaCl, 2% formaldehyde, 2% glutaraldehyde and 2 mM CaCl2). Lungs were 
removed and cut into pieces of about 5 x 5 x 5 mm and immersed in Caco-buffer over 
night. After washing 4x15 min in PBS, the tissue pieces were immersed in PBS 
containing 1% OsO4 followed by washing 4 x 15 min in aqua bidest. Dehydration was 
performed by a graded EtOH-series and embedded in Epon. Thin sections were cut 
and stained with uranyl acetate and lead citrate. Electron microscopy pictures were 
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digitally recorded using a Zeiss EM10. These experiments were done by cooperating 
group of Prof. W. Baumgartner, RWTH Aachen.  
 
3.2.6.1 In situ fluorescence microscopy 
In situ imaging of endothelial NO production was performed by cooperating group of 
Prof. W. Kuelber, Institute for Physiology, Charité – Universitätsmedizin Berlin as 
previously described [345]. In brief, lungs were excised and continuously perfused 
with 14 mL/min autologous blood at 37°C. Lungs were constantly inflated with a gas 
mixture of 21% O2, 5% CO2, and balance N2 at a positive airway pressure (PAW) of 5 
cm H2O. Left atrial pressure (PLA) was set to 3 cm H2O, yielding pulmonary artery 
pressure (PPA) of 10±1 cmH2O. PAW, PLA, and PPA were continuously monitored 
and recorded (DASYlab 32; Datalog GmbH, Moenchengladbach, Germany). Lungs 
were positioned on a custom-built vibration-free microscope stage and superfused 
with normal saline at 37°C. 
For in situ imaging of endothelial NO production, membrane-permeant DAF-FM 
diacetate (5 µM/L), which de-esterifies intracellularly to cell-impermeant, NO-
sensitive DAF-FM was infused for 20 min into pulmonary capillaries via a venous 
microcatheter. Intracellular DAF-FM is converted by an NO-dependent, irreversible 
reaction to an intensely fluorescent benzotriazole derivative with fluorescence 
intensity linearly reflecting NO concentration [346]. Single venular capillaries were 
viewed at a focal plane corresponding to maximum diameter (17-28 µm). Endothelial 
DAF-FM fluorescence was excited at 480 nm by a near monochromatic beam 
generated by a digitally controlled galvanometric scanner (Polychrome IV; TILL 
Photonics, Martinsried, Germany) from a 75-watt xenon light source. Fluorescence 
emission was collected through an upright microscope (Axiotechvario 100HD; Zeiss, 
Jena, Germany) equipped with an apochromat objective (UAPO 40x W2/340; 
Olympus, Hamburg, Germany) and dichroic and emission filters (FT 510, LP 520; 
Zeiss, Jena, Germany) by a CCD camera (Sensicam; PCO, Kelheim, Germany) and 
subjected to digital image analysis (TILLvisION 4.0; TILL Photonics). Exposure time 
for each single image was limited to 5 milliseconds. Fluorescence images obtained in 
10s intervals were background-corrected and fluorescence intensity (F) was 
expressed relative to its individual baseline (F0). Since the conversion of DAF-FM to 
the benzotriazole derivative is irreversible, NO production is reflected by changes of 
the ratio F/F0 (∆F/F0) over time and was determined in 5 min intervals. At the end of 
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experiments, the exogenous NO donor SNAP (1 mmol/L) was added to test whether 
endothelial cells still contained unconverted DAF-FM.  
 
3.2.7 Measurement of alveolar fluid influx and reabsorption 
Fluid fluxes into and out of the alveolar space were quantified by a double-indicator 
dilution technique by cooperating group of Prof. W. Kuelber, Institute for Physiology, 
Charité – Universitätsmedizin Berlin as previously reported [347]. Briefly, a high-
molecular-weight fluorescence tracer, texas red dextran (70 kDa; Molecular Probes, 
Eugene, OR), was instilled into the alveolar space for determination of alveolar net 
fluid shift while a low-molecular-weight tracer, Na+ fluorescein (376 Da; Sigma-
Aldrich, Taufkirchen, Germany), was added to the perfusate to allow for 
differentiation between alveolar fluid influx and alveolar fluid reabsorption. At time -10 
min, 0 min, and 60 min, samples were drawn from both compartments, and alveolar 
fluid reabsorption, alveolar fluid influx, and net fluid shift were calculated as 
previously described assuming a two-compartmental distribution model [347].  
 
3.2.8 Statistics 
In case of heteroscedasticity, data were transformed by the Box-Cox transformation 
prior to analysis. Data were analysed by an unpaired t-tests or by the Dunnett test 
(JMP1 statistical software version 7; JMP Germany, Böblingen, Germany). 
Fluorescence data were analysed by the Kruskal–Wallis and Mann–Whitney U-test. If 
required, p-values were corrected for multiple comparisons according to the false-
discovery rate procedure using the ‘‘R’’ statistical package (R Foundation for 
Statistical Computing, Vienna, Austria) 
                                                                                                                                                                         Results 
 52
4 Results 
We have performed most of our experiments in isolated perfused rat and mouse 
lungs. This model was selected for following reasons: a) In isolated lungs the indirect 
effects of PAF like activation of neutrophils and increasing hydrostatic pressure can 
be excluded by perfusion with blood-free buffer and by keeping hydrostatic pressures 
constant. Thus, this model allows studying exclusively the direct effects of PAF on 
lung vascular permeability. b) PAF does not increase vascular permeability in 
endothelial cell monolayers in culture [274, 337]. Therefore, at present the effects of 
PAF on vascular permeability are best studied in isolated perfused lungs. Further 
more, this method is suited for the measurement of following parameters that would 
be extremely difficult to measure in vivo: The vascular filtration coefficient [341], the 
quantification of alveolar fluid clearance and secretion [347], and the in situ 
fluorescence imaging of nitric oxide production [345] and Ca2+ concentration [348] in 
endothelial cells. 
 
4.1 PAF induced edema formation 
Isolated rat lungs were perfused for 40 minutes under control conditions before 5 
nmol of PAF was injected into the artery. This resulted a rapid and brief increase in 
lung weight. The ASM inhibitor Imipramine was given 10 minutes before PAF and 
impaired the PAF-induced edema formation about 50%. Figure 16 shows both the 
real time curve (a) and summarized weight gain (b) of edema formation from PAF 
treated (50 nM) and untreated control lungs. 
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Fig. 16: PAF-induced edema formation. a) The real time curve and b) The summarized 
weight gain in lungs perfused under control conditions and PAF-treated (10 min after bolus 
injection of 5 nmol PAF). Data are presented as mean±SD, n=4. *: p<0.05 versus control. 
 
4.2 PAF induced caveolin recruitment and endothelial nitric oxide 
synthase (eNOS) distribution 
4.2.1 Number and size of caveolae 
Caveolin-1 is the essential molecule of caveolae, thus in cooperation with Prof. W. 
Baumgartner, RWTH Aachen, we examined whether PAF-treatment increased the 
number or size of caveolae by electron microscopic images of microvascular 
endothelial cells from isolated perfused lungs (Fig. 17). It turned out that PAF did not 
increase the number of apical, cellular or basal caveolae (Fig. 17, panel c), nor did it 
increase the size of caveolae: the maximal diameter at the centre of caveolae was 
152±26nm (n=103, from one lung) in control and 148±26nm (n=106, from one lung) 
in PAF-treated lungs. Furthermore, in PAF-treated lungs, we repeatedly observed 
loosening of the endothelial adherence junctions between cells in the capillaries (Fig. 
17, panel b).  
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Fig. 17: Number and size of caveolae. Electron microscopic images of endothelial cells 
showing junctions and caveolae in a) control and b) PAF treated lungs. c) Number of apical, 
basal and intracellular caveolae in endothelial cells from control and PAF treated lungs. 95–
106 apical, basal and intracellular caveolae were counted from one control and one PAF-
treated lung. These experiments were performed by cooperating group of Prof. W. 
Baumgartner.  
 
4.2.2 Preparation and characterisation of caveolae 
Since sphingolipids, eNOS and other signalling proteins are enriched in caveolae, we 
investigated whether PAF alters the composition of caveolae in pulmonary 
endothelial cells. Therefore we established a method originally described by 
Schnitzer et al [284]. This protocol allowed us to isolate caveolae from the endothelial 
cells of isolated perfused rat lungs.  
Lungs were perfused for 50 min before perfusion with the colloidal silica beads was 
started in order to prepare endothelial cell membrane fractions. Immunoblotting of the 
resulting fractions shows a typical distribution for Cav-1: two bands are typical for rat 
Cav-1 representing Cav-1α and Cav-1ß [261]. To increase the amount of material 
available for subsequent analyses, we pooled the 17 fractions into five fractions 
labelled 0 and A–E. We also found the flotillin-1 (another lipid raft marker) in fractions 
B-E (data not shown), meanwhile the angiotensin converting enzyme (ACE, a non-
caveolar plasma membrane protein, Fig. 18), lysosomal-associated marker protein-1 
(LAMP-1, a lysosomal marker, data not shown) and transferrin receptor (non-raft 
membrane marker, data not shown) were only found in highest density fractions. In 
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line with the sucrose concentrations, the presence of Cav-1 and the absent or weak 
signals for ACE and other non-caveolar markers, we consider fractions B and C to 
represent caveolae, while fraction D may represent a mixture of caveolar and non-
caveolar structures. 
 
 
 
Fig. 18: Caveolin-1 identification of pulmonary endothelial cell plasma membrane fractions. 
a) Immunoblots showing the Cav-1 distribution in pulmonary endothelial cell plasma 
membrane fractions from untreated control and PAF-treated (10 min after bolus injection of 5 
nmol PAF) isolated perfused rat lungs. b) Immunoblots showing the angiotensin converting 
enzyme (ACE) distribution in pulmonary endothelial cell plasma membrane fractions from 
control and PAF (5 nmol) treated isolated perfused rat lungs. 
 
4.2.3 PAF recruits caveolin-1 to caveolar fraction 
PAF caused an increase in the amount of Cav-1 in several fractions from pulmonary 
endothelial cells (Fig. 19) and the effect of PAF was clearly noticeable in the pooled 
fractions. The strongest increase in Cav-1 was noted in the fractions B, C and D. To 
demonstrate that Cav-1 was recruited to the caveolae, we measured the abundance 
of Cav-1 in whole cell lysates, in the pooled fractions B/C representing the caveolae 
and in the remainder of the cells (fractions A, D, E and pellet) representing the non-
caveolar fractions. Our findings show that the total amount of Cav-1 was unchanged 
in the total endothelial cell lysate but that it was increased in the caveolar fractions 
and decreased in the remaining fractions. 
                                                                                                                                                                         Results 
 56
Fig. 19: PAF increases caveolin-1 in caveolae. a) Pooled immunoblots showing Cav-1 
distributions from untreated control condition (n=4) and PAF-treated (10 min after bolus 
injection of 5 nmol PAF, n=4) isolated perfused rat lungs from fraction A–E. b) Immunoblots 
showing Cav-1 in fractions from whole endothelial cells (n=3), from the pooled fractions B 
and C (n=3) and from the remainder of the endothelial cells without the fractions B and C 
(n=3). The latter two fractions (B/C and the remainder) were obtained from the same 
preparation. Data are presented as mean±SD. *: p <0.05 versus control. 
 
4.2.4 Role of endothelial caveolar eNOS and NO production 
It is known that Cav-1 binds and thereby blocks eNOS activation [307, 349], we 
investigated the effects of PAF on the abundance of eNOS inside caveolae and on 
endothelial NO production. As seen in Fig. 20, PAF increased the amount of eNOS 
inside the caveolar fractions B and C. 
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Fig. 20: Effect of PAF on caveolar eNOS. Immunoblots showing the eNOS distribution in 
pooled pulmonary endothelial cell plasma membrane fractions from untreated control 
condition and PAF-treated (10 min after bolus injection of 5 nmol PAF) isolated perfused rat 
lungs. Data are presented as mean±SD, n=4. *: p<0.05 versus control. 
 
Our cooperating group of Prof. W.M. Kuebler used the DAF-FM loaded lung capillary 
endothelial cells to measure the NO production in situ. As seen in Fig. 21, PAF 
treatment markedly reduced basal endothelial NO production. Comparatively, NO 
production remained stable and continuous in untreated control lungs and was 
completely blocked after addition of the NO synthase inhibitor L-NAME.  
 
 
 
 
 
                                                                                                                                                                         Results 
 58
 
Fig. 21: Effect of PAF on endothelial NO production. Endothelial NO production as 
determined by in situ real-time fluorescence microscopy shown as 5 min averages in 
untreated control condition, under PAF-treated (bolus injection of 5 nmol PAF after baseline 
recording) and L-NAME (250 µM) treated lungs. NO production was quantified as increase in 
fluorescence of DAF-FM loaded endothelial cells over 5 min intervals relative to baseline Δ 
(F/F0). Data are presented as mean±SEM, n=5. *: p<0.05 versus control. These experiments 
were performed by cooperating group of Prof. W. Kübler.  
 
4.2.5 Effects of NO on PAF-induced edema formation 
In order to analyse the effects of NO on PAF-induced edema formation, we used the 
NO donor PAPA-NONOate to increase the exogenous NO level and L-NAME to 
decrease the NO concentration by blocking the eNOS activity. Both agents did not 
alter lung weight by sole perfusion. By perfusing lungs together with PAF, PAPA-
NONOate attenuated PAF-induced edema formation, while L-NAME had no effect. 
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Fig. 22: Effect of NO on PAF-induced edema formation. Weight gain in lungs perfused under 
untreated control condition (n=11), with PAF treated (10 min after bolus injection of 5 nmol 
PAF, n=12), NONOate/PAF (100 µM NONOate, n=7), L-NAME/PAF (250 µM L-NAME, n=8), 
NONOate (n=3) or L-NAME (n=3). The pharmacological agents were added after 30 min of 
perfusion and PAF after 40 min of perfusion. Data are presented as mean±SD. *: p<0.05 
versus control; #: versus PAF. 
 
4.2.6 The filtration coefficient measurement 
The filtration coefficient (Kf), proportionality constant represents the hydraulic 
conductance of the pulmonary endothelium. To complement the weight gain 
experiments, we measured the Kf in isolated perfused rat lungs with an established 
method [341]. Panel a in Fig. 23 illustrates the typical Kf measurement manoeuvre 
demonstrating the weight transient induced by the pressure jump and that was 
reversible even after PAF administration, which is critical requisite for the Kf 
measurement. As seen in panel b, the NO donor PAPA-NONOate did not affect the 
Kf, whereas L-NAME increased the Kf to approximately half the value as PAF did. 
Given 10 min before PAF, PAPA-NONOate attenuated the PAF-induced Kf increase, 
whereas L-NAME had no effect.  
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Fig. 23: The filtration coefficient measurement. a) Weight gain curve in a typical experiment 
with administration of PAF and determination of the filtration coefficient. For the Kf 
measurement perfusion pressure was raised by 5 cm H2O for 15 min and reduced back to 
baseline. Both weight transients (up, down) were used to calculate the Kf. b) Kf determined 
as the difference in Kf before and 10 min after PAF administration. Kf in lungs perfused under 
control condition (n=3), with PAF treated (10 min after bolus injection of 5 nmol PAF, n=4), 
NONOate/PAF (100 µM, n=3), L-NAME/PAF (250 µM, n=3), NONOate alone (n=3) or L-
NAME alone (n=3). The pharmacological agents were added after 30 min of perfusion and 
PAF after 40 min of perfusion. Data are presented as mean±SD. *: p<0.05 versus control; #: 
versus PAF. 
 
4.2.7 Alveolar fluid influx, alveolar fluid absorption 
As NO has been known to be involved in the regulation of the epithelial barrier 
functions [347], it was important to know whether the intravascular application of PAF 
would alter alveolar fluid influx or absorption. Using a double-indicator technique and 
assuming a two-compartmental distribution model [347], our cooperating group found 
that PAF did not alter the alveolar barrier properties (see Fig. 24). 
 
                                                                                                                                                                         Results 
 61
 
Fig. 24: Alveolar fluid influx and alveolar fluid absorptio. a) Alveolar fluid influx. b) Alveolar 
fluid absorption in untreated control lungs, in PAF-treated (5 nmol) lungs and in lungs 
exposed to 20 cm H2O hydrostatic pressure for 60 min. Data are presented as mean±SEM, 
n=3. *: p<0.05 versus control. These experiments were performed by cooperating group of 
Prof. W. Kübler.  
 
4.3 PAF activates ASM to decrease endothelial NO production 
4.3.1 PAF increased ASM activity 
After 10 minutes perfusion with PAF, ASM activity was increased in the fractions A–
C. Imipramine which could prevent the PAF-induced activation of ASM [111] 
evidently impaired the PAF induced increase in ASM activity in the membrane 
fractions (Fig. 25).  
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Fig. 25: Acid sphingomyelinase (ASM) activity in pulmonary endothelial cell plasma 
membrane fractions from isolated perfused rat lungs. Membrane fractions in lungs perfused 
for 50 min are shown under control condition, with PAF treated (10 min after bolus injection 
of 5 nmol PAF) and imipramine/PAF (100 µM imipramine). Data are presented as mean±SD, 
n=4. *: p<0.05, **:  p<0.01 versus PAF. 
 
4.3.2 Role of ASM on PAF-induced edema formation and Cav-1 recruitment 
Imipramine and D609, two structurally different inhibitors of the ASM pathway [156] 
were perfused 10 minutes before PAF administration. These two ASM inhibitors 
significantly prevented the PAF-induced edema formation (Fig. 26) and recruitment of 
Cav-1 to caveolar membrane fractions (Fig. 27) 
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Fig. 26: Effects of acid sphingomyelinase (ASM) pathway inhibitors on PAF-induced edema 
formation. Weight gain in lungs perfused under control conditions, with PAF (10 min after 
bolus injection of 5 nmol PAF), imipramine/PAF (100 mM imipramine), D609/PAF (300 mM 
D609) or ARC39/PAF (1 µM ARC39). The pharmacological agents were added after 30 min 
of perfusion and PAF after 40 min of perfusion. Data are presented as mean±SD, n=4 *: p 
<0.05 versus PAF. 
 
 
 
Fig. 27: Effects of acid sphingomyelinase (ASM) pathway inhibitors on caveolin-1 
recruitment. Immunoblots showing the Cav-1 distribution in pooled pulmonary endothelial cell 
plasma membrane fractions prepared from lungs treated with PAF (10 min after bolus 
injection of 5 nmol PAF), imipramine/PAF (100 mM imipramine), D609/PAF (300 mM D609) 
or ARC39/PAF (1 µM ARC39). The pharmacological agents were added after 30 min of 
perfusion and PAF after 40 min of perfusion. Data are presented as mean±SD, n=4. *: p 
<0.05 versus PAF. 
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4.3.3 Role of ASM on eNOS distribution 
Coincident to Cav-1, the ASM inhibitors imipramine and D609 also significantly 
prevented the PAF-induced level of eNOS in caveolar membrane fractions (Fig. 28).  
 
 
 
Fig. 28: Effects of acid sphingomyelinase (ASM) pathway inhibitors on the caveolar 
expression of eNOS. Immunoblots showing the eNOS distribution in pooled pulmonary 
endothelial cell plasma membrane fractions prepared from lungs treated with PAF (10 min 
after bolus injection of 5 nmol PAF), imipramine/PAF (100 mM imipramine) or D609/PAF 
(300 mM D609). The pharmacological agents were added after 30 min of perfusion and PAF 
after 40 min of perfusion. Data are presented as mean±SD, n=4. *: p <0.05 versus PAF. 
 
4.3.4 Role of ASM on NO production 
In addition to analysis of eNOS distribution in caveloae, our cooperating group also 
measured the NO production under PAF and ASM inhibitor administration with In situ 
fluorescence microscopy. Imipramine attenuated the PAF-induced decrease in 
endothelial NO production (Fig. 29, panel a and b). Imipramine alone had no effect 
on basal NO production, as demonstrated by the unaltered NO production rates 
during the 10 minutes that imipramine was infused without PAF. 
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Fig. 29: Effects of ASM on PAF-mediated endothelial NO production. Panel a) represent 
fluorescence images of DAF-FM loaded lung venular capillaries in isolated perfused rat 
lungs. Images were obtained at baseline and 10 min after PAF (5 nmol) stimulation in control 
lungs and in lungs perfused with imipramine (100 µM). The pharmacological agents were 
added 10 min prior to PAF infusion. Note that due to the irreversible conversion of the 
fluorescent dye, absence of fluorescence increase as seen in PAF treated controls indicates 
lack of NO synthesis. Panel b) shows endothelial NO production as determined by in situ 
real-time fluorescence microscopy. Curves are shown as 5 min averages at baseline and 
after stimulation with PAF alone and with PAF plus imipramine perfused lungs. NO 
production was quantified as increase in fluorescence of DAF-FM loaded endothelial cells 
over 5 min intervals relative to baseline (∆F/F0). Data are presented as mean±SEM, n=5. *: 
p<0.05 versus PAF. These experiments were performed by cooperating group of Prof. W. 
Kübler. 
 
4.3.5 Effects of ASM perfusion and ASM depletion on NO production 
In order to further demonstrate the role of ASM on NO synthesis, our cooperating 
group repeated the NO production measurement with ASM perfusion instead of PAF. 
As seen in panel a, figure 30, direct perfusion with ASM (1 U/mL) decreased 
endothelial NO production to the same extent as PAF did. As opposed to wild-type 
mice, PAF did not decrease endothelial NO production in lungs of ASM deficient mice 
(panel b, Fig. 30). Together with previous findings, it shows that PAF stimulates the 
ASM which in turn leads to the recruitment of Cav-1 and eNOS to caveolae with a 
subsequent inhibition of endothelial NO production that promotes lung edema 
formation. 
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Fig. 30: Effects of ASM perfusion and ASM depletion on NO production. a) ASM perfusion 
reproduced the PAF response on endothelial NO production Images were obtained at 
baseline and 10 min after ASM (1 U/mL) stimulation in control lungs. b) Endothelial NO 
response to PAF in ASM-deficient mice. Data are shown as wild-type (WT) control mice, PAF 
(5 nmol) treated wild type mice, and ASM deficient mice. Endothelial NO production were 
determined by in situ real-time fluorescence microscopy of lung venular capillaries in isolated 
perfused mouse lungs. Data are presented as mean±SEM, n=5. *: p<0.05 versus WT 
control. These experiments were performed by cooperating group of Prof. W. Kübler.  
 
4.4 PAF activates ASM to increase endothelial Ca2+ levels 
Previous studies had shown that PAF-triggered edema is partially mediated by Ca2+ 
release, influx from extracellular and subsequent Ca2+ dependent activation of 
myosin light chain kinase (MLCK) in endothelial cells [322-323]. Consequently, PAF-
induced edema formation could be attenuated by the IP3 receptor blocker 
xestospongin, the myosin light chain kinase inhibitor ML-7, or removal of extracellular 
Ca2+ [350]. Recently, polymodal sensory channels of the transient receptor potential 
(TRP) family have emerged as major regulators of lung endothelial barrier function. 
Unlike the members of the vanilloid (TRPV) and melastatin (TRPM), canonical 
(TRPC) channels wre shown to mediate primarily agonist-induced permeability 
changes [63]. 
In this work, we have tested the hypothesis that PAF may stimulate endothelial Ca2+ 
signalling and subsequent changes in microvascular permeability by activating TRP 
channels via the ASM. We performed experiments in isolated perfused rat and 
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mouse lungs to isolate and identify the TRPC channels, measure the cytosolic Ca2+ 
concentration and analyse the vascular permeability and edema formation. 
 
4.4.1 Role of TRPC channels in PAF-induced edema formation and endothelial 
[Ca2+]i 
In order to investigate the role of TRP channels in the PAF response, we used the 
SKF96365 as TRPC blocker. As seen in Fig. 31, the SKF96365 attenuated the PAF-
induced edema by about 50% and reduced the [Ca2+]i as well. Since TRPV channels 
are also known to promote vascular barrier failure [351-352], it was also necessary to 
examine the involvement of TRPV channels in PAF-induced edema formation of 
isolated perfused rat lung. We use retheuium red as the TRPV inhibitor and it turned 
out retheuium red had no significant effect neither on edema formation nor 
endothelial [Ca2+]i increase. 
 
Fig. 31: Effects of TRPC channels blocker in PAF-induced edema formation and endothelial 
[Ca2+]i. a) Edema formation was assessed by weight gain in lungs under untreated control 
condition, with PAF-treated (10 min after bolus injection of 5 nmol PAF), SKF96365/PAF (30 
µM SKF96365) and retheuium red/PAF (1 µM retheuium red). The pharmacological agents 
were added after 30 min of perfusion and PAF after 40 min of perfusion. Data are presented 
as mean±SD, n=4. *: p< 0.05 versus control, #: p< 0.05 versus PAF. b) PAF stimulates 
endothelial Ca2+ influx via TRPC channels. Endothelial [Ca2+]i was determined by in situ real-
time fluorescence microscopy of fura-2 loaded lung venular capillaries in isolated perfused 
rat lungs. Data are shown as 5 min averages in PAF (5 nmol) stimulated control lungs and 
PAF stimulated lungs that had been pretreated with SKF96365 (30 μM) or ruthenium red (1 
μM). *: p<0.05 versus PAF alone, Data are presented as mean±SEM, n=5. The in situ real-
time fluorescence experiments were performed by cooperating group of Prof. W. Kübler.  
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4.4.2 PAF induced TRP channels recruitment in caveolae 
To identify the TRPC channels that mediates the endothelial intracellular Ca2+ 
concentration ([Ca2+]i) in response to the PAF and ASM administration, we have 
systematically probed the abundance of several TRPC channels (TRPC1, TRPC3, 
TRPC4, TRPC5, TRPC6) in caveolae of control and PAF treated lungs. By 
cooperation with Prof. Veit Flockerzi, we have identified that PAF stimulates the 
expression of TRPC6 channels in caveolae (Fig. 33), and the rest of the TRPC 
members were not present. 
 
 
 
Fig. 33: PAF increases the abundance of TRPC6 channels in caveolar fractions of lung 
endothelial cell membrane. a) Representative immunoblots show TRPC6 expression in 
caveolar fractions freshly isolated 10 min from untreated control and after treatment of 
isolated rat lungs with a bolus of 5 nmol PAF. b). Densitometric measurements of 4 
independent experiments. Data are presented as mean±SD, n=4. *: p< 0.05 versus control.  
 
To examine whether TRPC6 channels play a role in the PAF-induced edema 
formation, we measured the endothelial [Ca2+]i in isolated lungs from TRPC6 deficient 
mice. As seen in Fig. 32, both the PAF-induced increased in weight gain and 
endothelial [Ca2+]i markedly reduced in the lungs of TRPC6 knockout mice. 
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Fig. 32: PAF-induced edema formation and endothelial [Ca2+]i responses in TRPC6-deficient 
mice. a) Edema formation was assessed by the real time curve in lungs from wild type and 
TRPC6 knockout mice with PAF-treated (10 min after bolus injection of 25 nmol PAF). Data 
are presented as mean±SD, n=4. *: p< 0.05 versus wild type. b) Endothelial [Ca2+]i was 
determined by in situ real-time fluorescence microscopy of lung venular capillaries in isolated 
perfused mouse lungs. Data are shown as PAF (10 min after bolus injection of 5 nmol PAF) 
treated lungs of wild type and TRPC6 deficient mice. Time point of PAF administration is 
indicated by arrow.*: p<0.05 versus wild-type control, Data are presented as mean±SEM, 
n=5. The in situ real-time fluorescence experiments were performed by cooperating group of 
Prof. W. Kübler. 
 
4.4.3 Role of ASM in PAF induced TRPC6 recruitment 
ARC39 is a newly developed ASM inhibitor [353] that reduced edema formation in 
isolated perfused rat lung model (as seen Fig. 26). Here we use ARC39 to analyse 
the effects of ASM in PAF induced TRPC6 recruitment. As seen in Fig. 34, ASM 
inhibition by ARC39 significantly impaired TRPC6 recruitment into caveolae fractions.  
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Fig. 34: Effects of ASM inhibition on PAF induced TRPC6 recruitment. a) Immunoblots 
showing TRPC6 distributions from ARC39/PAF (1 µM ARC39) and PAF (10 min after bolus 
injection of 5 nmol PAF) treated isolated perfused rat lungs from fraction A–E. b) TRPC6 
distribution in caveolae fractions (summary of pooled fraction B-E). *: p<0.05 versus PAF. 
Data are presented as mean±SD, n=4. 
 
4.4.4 Role of ASM on endothelial [Ca2+]i 
In addition to the analysis of TRPC6 distribution in caveloae, our cooperating group 
also measured the endothelial [Ca2+]i under PAF and ASM inhibitor administration 
with in situ fluorescence microscopy. Imipramine attenuated the PAF-induced 
increase in endothelial [Ca2+]i (Fig. 35, panel a and b), but had no effect on basal 
Endothelial [Ca2+]i increase in the first 10 minutes when it was given before PAF. 
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Fig. 35: Effects of ASM on PAF-mediated endothelial [Ca2+]i. Panel a) shows fluorescence 
images of fura-2 loaded lung venular capillaries in isolated perfused rat lungs. Images were 
obtained at baseline and 10 min after PAF (5 nmol) stimulation in control lungs and in lungs 
perfused with imipramine (100 µM). The pharmacological agents were added 10 min before 
PAF infusion. Panel b) shows endothelial [Ca2+]i as determined by in situ real-time 
fluorescence microscopy. Curves are shown as 5 min averages at control, after stimulation 
with PAF alone and with PAF plus imipramine perfused lungs. [Ca2+]i was quantified as 
increase in fluorescence of fura-2 loaded endothelial cells over 5 min intervals relative to 
baseline (∆F/F0). Data are presented as mean±SEM, n=5. *: p<0.05 versus PAF. These 
experiments were performed by cooperating group of Prof. W. Kübler. 
 
4.4.5 Effects of ASM perfusion and ASM depletion on endothelial [Ca2+]i 
For further demonstration of the role of ASM in endothelial [Ca2+]i regulation, our 
cooperating group repeated the endothelial [Ca2+]i measurement with ASM perfusion 
instead of PAF. As seen in panel a, Fig. 36, Direct perfusion with ASM (1 U/mL) 
increased endothelial [Ca2+]i to the same extent as PAF. As opposed to wild-type 
mice, PAF did not increase endothelial [Ca2+]i in lungs of ASM deficient mice (panel 
b, Fig. 36). Together with previous findings, it shows that PAF stimulates the ASM 
which in turn leads to the recruitment of Cav-1 and TRPC6 to caveolae with a 
subsequent influx of Ca2+ that promotes lung edema formation. 
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Fig. 36: Effects of ASM perfusion and ASM depletion on [Ca2+]i. a) ASM perfusion 
reproduced PAF response of endothelial [Ca2+]i. Images were obtained at baseline and 10 
min after ASM (1 U/mL) stimulation in control lungs. b) Endothelial [Ca2+]i response to PAF in 
ASM-deficient mice. Data are shown as wild-type (WT) control mice, PAF (5 nmol) treated 
wild type mice, and ASM deficient mice. Endothelial [Ca2+]i were determined by in situ real-
time fluorescence microscopy of lung venular capillaries in isolated perfused mouse lungs. 
Data are presented as mean±SEM, n=5. *: p<0.05 versus WT control. These experiments 
were performed by cooperating group of Prof. W. Kübler. 
 
4.4.6 Recomposing of PAF response:  Hyperforin, sulprostone and L-NAME  
Our current hypothesis is that the PAF-induced edema formation has composed 
three components: a) The activation of cyclooxygenase (COX), production of PGE2 
and activation of EP3 receptors [152]. b) The discontinuation of endothelial NO 
production induced by ASM activation and caveolin-1 recruitment. c) Endothelial cell 
constriction induced by calcium influx though TRPC6 channels in caveolae. Here we 
used hyperforin as a TRPC6 agonist [354], and together with the sulprotone which is 
a EP1/3-receptor agonist [152] and L-NAME as eNOS inhibitor to further investigate 
the role of TRPC6 and EP1/3 receptors in edema formation. As seen in Fig. 37, both 
hyperforin (10 µM) and sulprostone (1 µM) perfusion alone did increase weight gain 
of the perfused rat lungs where L-NAME (100 µM) did not; perfusion with L-NAME 
and hyperforin increased weight gain another 50% above; perfusion of L-NAME 
together with hyperforin and sulprostone gave a weight gain of almost 400mg, of 
note, this value is close to the 550mg that are achieved by PAF. 
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Fig. 37: Role of hyperforin and sulprostone in edema formation. Weight gain in lungs 
perfused under control conditions (n=4), or with L-NAME (100 µM) alone, with sulprostone (1 
µM) alone, with hyperforin (10 µM) alone, with L-NAME plus hyperforin and with L-NAME 
plus hyperforin and sulprostone. The L-NAME was added after 30 min of perfusion and 
sulprostone and hyperforin after 40 min of perfusion. Data are presented as mean±SD, n=3 
*: p <0.05 versus control, #: p <0.05 versus preceding columns. 
 
4.5 Effects of steroids 
To elucidate the short-term anti-inflammatory effects of steroids that are still poorly 
understood, we studied the effects of dexamethasone and quinine on edema 
formation, Cav-1 and eNOS recruitment, NO production. Dexamethasone was 
previously shown to prevent the PAF-induced edema formation by down-regulating 
ceramide production [111], and quinine was shown to block PAF-induced edema by 
affecting intracellular calcium levels [151, 355-356]. As seen in Fig. 38, 
dexamethasone perfusion provided a pharmacological approach to block ASM 
activity. 
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Fig. 38: Acid sphingomyelinase (ASM) activity in pulmonary endothelial cell plasma 
membrane fractions from isolated perfused rat lungs. Showns are the membrane fractions in 
lungs perfused for 50 min under untreated lungs and treated with PAF (10 min after bolus 
injection of 5 nmol PAF) or dexamethasone/PAF (10 µM dexamethasone). Data are 
presented as mean±SD, n=4. *: p<0.05, **:  p<0.01 versus PAF. 
 
Treatment of perfused rat lungs with dexamethasone and quinine both reduced the 
edema formation, but only dexamethasone perfusion reduced the abundance of Cav-
1 in the caveolar fractions of PAF-treated lungs (Fig. 39, panel b), whereas quinine 
had no effect on the enhanced expression of Cav-1 in PAF-stimulated lungs. 
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Fig. 39: Effects of steroids on edema formation and caveolin-1 recruitment. a) Edema 
formation was assessed by weight gain in control lungs and the lungs treated with PAF (10 
min after bolus injection of 5 nmol PAF), with dexamethasone (10 µM), with 
dexamethasone/PAF (10 µM dexamethasone) or with quinine/PAF (100 µM quinine). b) 
Immunoblots showing the Cav-1 distribution in pooled pulmonary endothelial cell plasma 
membrane fractions prepared from lungs perfused under control conditions, with PAF (10 
min after bolus injection of 5 nmol PAF), with dexamethasone (10 µM) alone, with 
dexamethasone/PAF (10 µM dexamethasone) or with quinine/PAF (100 µM quinine). The 
pharmacological agents were added after 30 min of perfusion and PAF after 40 min of 
perfusion. Data are presented as mean±SD, n=4. *: p <0.05 versus PAF. 
 
Moreover, dexamethasone attenuated the PAF-induced increase of caveolar eNOS 
expression (Fig. 40, panel a), the decrease in endothelial NO production (Fig. 40, 
panel b) and lung edema formation (Fig. 39, panel a).  
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Fig. 40: Effects of steroids on eNOS distribution and endothelial NO production. a) 
Immunoblots show the eNOS distribution in pooled pulmonary endothelial cell plasma 
membrane fractions prepared from lungs perfused under control conditions, with PAF-treated 
(10 min after bolus injection of 5 nmol PAF), dexamethasone (10 µM)alone,  
dexamethasone/PAF (10 µM dexamethasone) or quinine/PAF (100 µM quinine). Data are 
presented as mean±SD, n=4. *: p <0.05 versus PAF. b) Shown is the endothelial NO 
production as determined by in situ real-time fluorescence microscopy. Curves are shown as 
5 min averages at stimulation with PAF (5 nmol) alone and with dexamethasone plus PAF 
perfused lungs. NO production was quantified as increase in fluorescence of DAF-FM loaded 
endothelial cells over 5 min intervals relative to baseline (∆F/F0). Data are presented as 
mean±SEM, n=5. #: p<0.05 versus PAF. The in situ real-time fluorescence experiments were 
performed by cooperating group of Prof. W. Kübler. 
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5 Discussion 
Platelet-activating factor (PAF) is a potent pro-inflammatory mediator that elevates 
vascular permeability and leads to edema formation in pulmonary inflammation. 
Recently, it has been shown that PAF-induced edema formation is partly mediated by 
acid sphingomyelinase (ASM) [111]. The mechanisms by which ASM alters vascular 
permeability are poorly understood. 
The presence of sphingolipids in caveolae is well documented, where they contribute 
to the enhanced rigidity of membrane, but may also assume signalling functions. 
Caveolae are enriched in caveolins and endothelial NO synthase (eNOS), which is 
bound and thereby kept in its inactive state by caveolin-1 [81, 83]. Another important 
family of proteins present in caveolae are the transient receptor potential (TRP) 
channels [357-359]. In this thesis, we have linked PAF-induced ASM activation to the 
recruitment of caveolin-1, eNOS and TRPC6 to caveolae leading to decreased 
endothelial NO and increased endothelial [Ca2+]i levels, providing novel insights into 
the regulation of vascular permeability. In addition, in cooperation with Prof. 
Christoph Arenz (Humboldt University, Berlin) we have characterized the novel ASM 
inhibitor ARC39. 
In particular, we showed that a reduction in endothelial NO formation contributed to 
increased pulmonary vascular permeability under pathophysiological conditions 
mimicked by PAF. These findings are consistent with previous studies showing 
increased vascular permeability in eNOS-deficient mice [360]. Our findings further 
indicate that PAF reduced endothelial NO levels by the ASM-dependent recruitment 
of Cav-1 to caveolae with subsequent inhibition of eNOS, providing the first 
mechanistic explanation for the role of ASM in the development of pulmonary edema. 
Our findings may also provide a rationale for the treatment of pulmonary edema with 
exogenous NO or NO donors in order to restore normal endothelial NO levels. 
Furthermore, it was shown that PAF causes endothelial Ca2+ influx through TRPC6 
channels, probably after they have been recruited to caveolae. Thus, the ASM 
pathway contributes to PAF-induced edema formation by down-regulation of a 
protective factor, i.e. endothelial NO, and by up-regulation of endothelial [Ca2+]I that 
actively increases vascular permeability by causing endothelial cell contraction. 
Finally, our observations raise the hypothesis that interference with ASM activity 
inside caveolae may explain some of the short-term effects of steroids in the 
regulation of inflammation. 
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5.1 Regulation of caveolin-1 by PAF 
5.1.1 PAF induced caveolin-1 recruitment to caveolae 
Based on a procedure originally developed by Jan Schnitzer and colleagues, we 
established and improved a method to isolate caveolae from intact rat lungs in that 
we perfused isolated lungs with silica beads to tag the endothelial cells and separate 
their plasma membrane fractions in a sucrose gradient. Immunoblotting of the 
resulting fractions showed a typical distribution for Cav-1 predominantly in the 
fractions B-D which are expected to contain the caveolae (Fig. 18). Our study 
showed a rapid increase of Cav-1 in the caveolae fractions after stimulation with PAF 
(Fig. 19). The caveolae fractions are expected in the 10-16% sucrose gradient which 
roughly corresponds to our fractions B and C, which were largely devoid of 
angiotensin-converting enzyme and contained flotillin-1 (another caveolae or lipid raft 
marker). While fraction A (8-10% sucrose) and fraction D (20%-30%) may contain 
some caveolae, our data do not exclude the possibility that Cav-1 was recruited also 
to membrane fractions distinct from caveolae. Indirect evidence for the recruitment of 
Cav-1 in response to PAF is provided by the fact that at the same time PAF 
decreased endothelial NO production (Fig. 29). Caveolin-1 is well known to inhibit 
eNOS activity by a direct interaction with eNOS through its “scaffolding domain,” 
within endothelial caveolae [272, 317-318].  
As for the source of the Cav-1, our findings indicated that it translocates to the 
caveolae in response to PAF. Fig. 19 shows that the total amount of Cav-1 remains 
unchanged. The increase in the caveolae (fractions B/C) was matched by a decrease 
in the remainder of the cells. As this remainder consists of the entire cell except the 
caveolae, it is tempting to speculate that Cav-1 was recruited from inside the cell. In 
fact, recruitment of Cav-1 to the plasma membrane has previously been described for 
bovine aortic endothelial cells in response to shear stress [361], in models of 
coronary ischaemia reperfusion [362], portal hypertension [363] and liver cirrhosis 
[364].  
 
5.1.2 ASM and caveolin-1 distribution 
With respect to the molecular mechanisms that explain the Cav-1 recruitment, the 
reduction in NO synthesis, the entrance of calcium and thus the PAF-induced edema 
formation, it is of interest to examine the role of acid sphingomyelinase (ASM). The 
evidence supporting our conclusion that the PAF-induced redistribution of Cav-1 is 
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mediated by ASM is as follows: 1) Pharmacological ASM inhibitors (imipramine, 
D609, ARC39, steroids) and ASM-deficiency impaired PAF-induced pulmonary 
edema, NO production and the endothelial calcium increase (Fig. 26, 27, 29, 30). 2) 
While it has previously been shown that PAF increases circulating ASM levels, herein 
we demonstrate that PAF increases ASM activity inside endothelial caveolae (Fig. 
25). Since no reliable ASM antibodies are available we could not directly examine 
whether the increased activity is related to elevated amounts of the enzyme. 3) By 
measuring the ASM activity inside caveolar fractions we demonstrated that 
imipramine, which is not an enzyme inhibitor but accelerates the proteolytic 
degradation of ASM [156], reduced the ASM activity below baseline levels (Fig. 25). 
4) Injection of ASM reduced endothelial NO production and increased endothelial 
calcium levels, providing further evidence for the ability of ASM to affect NO 
production and calcium influx (Fig. 29). Unfortunately, the effect of ASM on Cav-1 
and edema formation could not be examined because such measurements had to be 
performed in an isolated lung model with 100 mL of recirculating buffer, so that the 
required amounts of ASM were beyond feasibility. 5) The reduction of caveolar ASM 
activity by imipramine resulted in reduced caveolar levels of Cav-1, eNOS and 
TRPC6 despite the presence of PAF, and inhibition of edema formation. The 
specificity of imipramine for ASM under these conditions is further supported by the 
finding that D609 and ARC39, the ASM-pathway inhibitors which are structurally 
completely unrelated to imipramine, also prevented the PAF-induced redistribution of 
Cav-1 (Fig. 26, 27) and TRPC6 (Fig. 34). 6) Finally, the same pattern of evidence as 
for imipramine could also be shown for dexamethasone. Dexamethasone was 
previously shown to prevent the PAF-induced increase in ceramide and edema 
formation [111]. Herein we show that dexamathasone prevented the PAF-induced 
increase of ASM activity in endothelial caveolae and all its sequelae such as Cav-1 
and eNOS recruitment to the plasma membrane, the loss of endothelial NO 
production and subsequent formation of lung edema (Fig. 39, 40). These findings are 
not only of interest because they corroborate the conclusions of our study, but also 
because they suggest a novel hypothesis on how to explain the poorly understood 
short term effects of steroids that have already been linked to caveolae [168]. It 
seems possible that steroids attenuate the formation of ceramide-rich microdomains, 
which are required for many signalling events, by interfering with the activation of 
ASM [156]. Other than acting as a signalling mediator, ceramide was suggested to 
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form microdomains on the membrane that are crucial for cell signalling [161-162, 
168-169]. Specific receptor molecules and signalling proteins like Cav-1, eNOS and 
calcium channels cluster within such platforms to exclude potential inhibitory signals, 
while initiating and greatly amplifying primary signals [156]. 
 
5.2 Endothelial permeability regulation by caveolin and NO in lungs 
5.2.1 Role of caveolin in the regulation of endothelial NO production 
Our caveolae isolation protocol permitted us to study in detail how PAF treatment 
alters the composition and the functional properties of the caveolar compartment and 
regulates NO production in situ. PAF treatment induced a rapid (<10 min) recruitment 
of both Cav-1 and eNOS into caveolae (panel b, c, Fig. 41) in parallel with increased 
ASM activity in caveolar fractions (panel d, Fig. 41). Furthermore, inhibition of ASM 
activity by ARC39 or imipramine blocked all these caveolar responses and prevented 
the PAF-induced cessation of NO production and the edema formation (panel a, Fig. 
41). Caveolins are well known to inhibit eNOS, so the increased caveolar levels of 
caveolin-1 can explain the impaired endothelial NO production in response to PAF 
(Fig. 29). All these findings indicated that the inhibition of endothelial NO production 
which contributed to PAF-induced edema was caused by ASM involved Cav-1 
recruitment to caveolae.  
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Fig. 41: Summary of PAF-induced changes in edema formation, caveolae, and ASM activity. 
Panel a shows weight gain of isolated perfused rat lungs 10 min after PAF treatment. Panel 
b: Immunoblot showing caveolin-1. Panel c: Immunoblot showing eNOS. Panel d: Enzymatic 
activity of acid sphingomyelinase. Lungs were infused with a bolus of 5 nMol PAF and 
pretreated 10 min before PAF administration with 10 μMol/L imipramine or dexamethasone. 
mean±SD, n=4. *: p<0.05 versus control. Data represent a summary from Fig. 25- 28, 38-40. 
 
5.2.2 Regulation of vascular permeability by NO 
Using the isolated perfused lung model we have shown, for the first time, that PAF 
rapidly attenuates endothelial NO production in pulmonary endothelium. This 
reduction of NO contributes to enhanced vascular permeability, as is illustrated by the 
effects of L-NAME and PAPA-NONOate on weight gain and Kf (Fig. 22, 23). This 
conclusion is concordant with altered endothelial junctional permeability in eNOS-
deficient or L-NAME-treated mice [365] and with the finding that endothelial NO 
synthesis reduces Kf in hydrostatic lung edema [338]. The finding that edema 
formation and endothelial NO reduction were prevented by ASM inhibitors imipramine 
or ARC39 (Fig. 26, 29) support the conclusion that this drop in endothelial NO 
production is regulated by ASM.  
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It is important to note that L-NAME alone had no effect on lung weight, but did only 
increase the Kf (Fig. 22). This is similar to the observation in eNOS-deficient mice 
that also showed increased vascular permeability but no lung edema [366]. These 
findings suggest that the role of the PAF-induced cessation of NO production is to 
amplify the increase in vascular permeability which is caused by another mechanism. 
Hence, along the PAF-ASM-axis additional mechanisms are likely to come into play, 
such as Ca2+ influx or PGE2 [111, 142].  
This conclusion is in accordance with the notion that the PAF-induced edema rests 
on different mechanisms, i.e. activation of the cyclooxygenase pathway [152] and 
acid sphingomyelinase (ASM)-dependent production of ceramide [111]. Accordingly, 
PAF-induced lung edema is attenuated, but not prevented by single agents that 
interfere with ceramide synthesis. In section 5.3.3, we will further discuss the 
interplay between the various mechanisms that constitute the PAF-induced edema 
formation. Here we would like to point the pathophysiological relevance of ASM that 
is further highlighted by the fact that several lung diseases are mitigated by genetic or 
pharmacological blockade of this enzyme [156]. In addition, elevated ASM activities 
are present in a variety of pathological conditions associated with increased vascular 
permeability such as models of acute lung injury and sepsis [111] as well as in septic 
human patients [367]. Thus, inhibition of ASM activity might be an interesting 
pharmacological target in inflammatory disorders.  
 
5.3 Caveolae, calcium influx and permeability regulation 
5.3.1 Caveolae as sites of calcium influx 
The important role of Ca2+ for pulmonary edema formation in general is well 
established [322-323]. In previous studies, it was observed that PAF-induced edema 
formation is dependent on an increase in intracellular Ca2+ concentration and on 
extracellular Ca2+ [350]. The rise of intracellular Ca2+ appears to be controlled by IP3-
dependent Ca2+ release from intracellular stores (e.g. ER). This conclusion is 
supported by the finding that inhibition of IP3 activation with L-108 (inhibitor of the PI-
specific phospholipase C) and Xestospongin C (specific IP3R antagonist) attenuated 
PAF-induced edema formation [350]. The role of extracellular calcium is supported by 
the finding that lanthanum chloride, an unspecific Ca2+-channel blocker [350], 
reduced PAF-induced edema. These findings are further corroborated by the 
observation that thapsigargin, an inhibitor of the endoplasmic reticulum Ca2+-ATPase, 
                                                                                                                                                                  Discussion 
 83
which is known to empty intracellular Ca2+ stores and activate SOC, induces edema 
formation in isolated rat lungs in a manner dependent on extracellular Ca2+ [368]. 
Thus, Ca2+ entry through store-operated Ca2+-channels (SOC) [369] or receptor-
operated Ca2+ channels (ROC) [275] in pulmonary edema formation is a well 
accepted paradigm. It is important to note that the IP3R has been described in the 
plasma membrane and especially in caveolae [81, 284-285]. In many reports it is also 
described that IP3R and TRPC channels are found in a multimeric-complex with 
caveolin-1 in membrane microdomains [327-329]. These observations support our 
assumption that caveolae are involved in PAF-induced vascular hyperpermeability. 
In endothelial cells of the rat mesentery, PAF increased cytoplasmic Ca2+ 
concentrations more than 5-fold within 1-2 min [365]. We now report similar 
observations in the pulmonary circulation. In particular, we demonstrated that 
perfusion with calcium-depleted media (data not shown) and with the non-selective 
TRPC blocker SKF96365 (Fig. 32) attenuated the PAF-induced endothelial [Ca2+]i 
increase and edema formation, while the unspecific TRPV blocker ruthenium red had 
no effect (Fig. 31). This finding led to cooperation with the group of Prof. Veit 
Flockerzi, in order to systemically probe the abundance of TRPC channels in 
caveolar fractions, which led to the discovery that among the TRPC channels only 
TRPC6 channels are recruited into caveolae by PAF (Fig. 33). To demonstrate the 
functional relevance of this finding, we studied TRPC6-deficient mice that showed 
greatly attenuated endothelial [Ca2+]i responses and edema formation (Fig. 32) in 
response to PAF. Again this pathway was linked to the ASM pathway because the 
increased endothelial [Ca2+]i was attenuated by genetic and pharmacological 
inhibition of ASM (Fig. 35, 36) and ASM perfusion reproduced the PAF response in 
edema and endothelial [Ca2+]i (Fig. 36). In summary, our data demonstrate that PAF 
increases endothelial Ca2+ levels, a mechanism that accounts for part of the PAF-
induced edema formation. The calcium enters the cells through TRPC6 channels that 
were recruited to caveolae in a ASM-dependent fashion (see also Fig. 42).  
As noted, regulation of pulmonary vascular permeability by calcium is a commonly 
accepted mechanism. In mesenteric venular microvessels [365], hamster cheek 
pouch [370] and human umbilical vein endothelial cells [371], PAF or thrombin 
increased endothelial permeability and  [Ca2+]i in a rapid manner. There are also 
evidences from frog, rat and hamster mesenteric venular microvessels showing that 
increased endothelial [Ca2+]i increased microvessel permeability [372-373]. Genetic 
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and pharmacological Ca2+-channels inhibition attenuated the increased endothelial 
permeability trigger by agents such as PAF, thrombin, VEGF and ATP [370-371, 373-
374]. It is commonly thought that MLCK and MLC phosphorylation which are in part 
regulated by Ca2+ lead to actino-myosin contraction with a subsequent increase in 
endothelial barrier permeability [66-67, 350]. In some extra-pulmonary tissues Ca2+ is 
also thought to act by activation of eNOS [375-376]; this discrepancy to the current 
findings is discussed in chapter 5.4.  
 
5.3.2 Calcium influx and endothelial permeability regulation by TRP channels 
We demonstrated that TRPC6 channels play a central role in endothelial calcium 
influx and the regulation of pulmonary vascular permeability. Our findings are in line 
with an increasing number of reports that implicate endothelial permeability with 
TRPC and TRPV channels.   
In general, TRPC4 and TRPC5 are considered to form store-operated calcium 
channels (SOC); TRPC1 may be also involved [323]. On the other hand, TRPC3, 
TRPC6 and TRPC7 form store-independent cation channels and are considered to 
function as receptor operated calcium channels (ROC) [54, 323, 377]. TRPC1, 
TRPC4 and TRPC6 are extensively expressed on endothelial cells, not only in the 
lungs but also in extra-pulmonary organs [378-382]. In isolated lungs and lung 
vascular endothelial cells from TRPC4 deficient mice, calcium influx induced by 
thrombin was drastically reduced, as well as the endothelial cell retraction response 
and the filtration coefficient (Kf) [371, 379]. In TRPC4-deficient confluent monolayers, 
thrombin-induced decreases of trans-endothelial resistance of cultured endothelial 
monolayers (a measure of endothelial permeability) were significantly smaller 
compared to wild type controls [383]. In addition, in the mouse aorta of TRPC4-
deficient mice, agonist-activated Ca2+ influx induced by acetylcholine and ATP was 
drastically decreased and this was associated with a markedly impaired endothelium-
dependent relaxation of blood vessels. 
Interestingly, there is already evidence that caveolin-1 may regulate TRPC channels. 
Rat and human in pulmonary artery endothelial cells PAEC express TRPC1, and it 
was suggested that TRPC1-mediated Ca2+-influx promotes endothelial cell shape 
change [378]. The cell permeant antennapedia-conjugated CSD peptide, which 
competes for protein binding partners with caveolin-1, markedly reduced thrombin-
induced Ca2+-influx via SOC [384] suggesting that caveolin-1 regulates calcium influx 
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via SOC by interaction with TRPC channels [385]. In another study, TRPC1 were 
shown to contribute to the calcium store-operated current (ISOC) which is essential for 
endothelial permeability regulation [386]. In addition, anti-TRPC1 antibodies inhibited 
the VEGF-induced calcium entry and the increased endothelial permeability in 
HUVECs. Finally, TRPC1 over-expression augmented the VEGF-induced calcium 
entry [374]. In future studies it will be highly interesting to examine whether caveolin-
1 and TRPC6 channnels can interact in a similar manner as caveolin-1 and TRPC1.   
As noted, TRPC-channels may form multimers. For instance, human umbilical 
endothelial cells (HUVECs) transfected with the N-terminal fragment of hTRPC3 to 
disrupt TRPC assembly, showed an absence of store-operated currents [382]. 
Clearly, our findings do not exclude the possibility that TRPC6-molecules are part of 
a multimeric complex, although by immunoblotting we were unable to detect TRPC3 
channels in the caveolae preparations. In our isolated perfused lung model, TRPC6 
regulated the calcium influx and hyperpermeability induced by PAF. In PAECs, 
TRPC6 knockdown prevented myosin light chain phosphorylation, actin stress fiber 
formation as well as inter-endothelial junctional gap formation in response to oleoyl-2-
acetyl-snglycerol or thrombinin [385]. Overexpression of a dominant negative TRPC6 
construct inhibited the VEGF-mediated increases in cytosolic calcium, migration, 
sprouting, proliferation and hyperpermeability in HUVECs [387]. TRPC6 also 
appeared to regulate calcium influx in perfused rana mesenteric microvessels [388]. 
Thus, our study further supports a critical role of TRPC6 channels in the regulation of 
vascular permeability and further suggests that its activity is regulated by the ASM. 
Another group of TRP channels that have been implicated in the regulation of 
pulmonary vascular permeability are TRPV channels. It was shown that the TRPV4 
channels is involved in the regulation of permeability induced by mechanical stress, 
[389]. In a study of high peak inflation pressure (PIP)-induced pulmonary 
hyperpermeability in isolated mouse lungs, calcium influx occurred though endothelial 
TRPV4 channel and TRPV inhibition by ruthenium red or TRPV4 deficiency 
attenuated the increase in Kf [390]. In isolated perfused rat/mouse lung model, 
elevation of lung microvascular perfuse pressure was shown to increase endothelial 
[Ca2+]i via activation of TRPV4 channels and the endothelial [Ca2+]i transient 
increased Kf via activation of myosin light-chain kinase [351]. In isolated lungs from 
TRPV4 deficient mice subjected to hypertension, hyperpermeability, calcium influx, 
and alveolar fluid volume were decreased compared to wild type mice [352]. In 
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addition, the TRPV4 activator 4α-phorbol-12,13-didecanoate (4α-PDD) increased 
lung endothelial permeability and the permeability response to 4α-PDD was absent in 
TRPV4 deficient mice [391-392].  For all these findings, it was important to exclude a 
role of TRPV4 channels in our model by showing that ruthenium red failed to affect 
the PAF-induced calcium responses and edema formation.   
 
5.3.3 Calcium influx, nitric oxide and cyclooxygenase act in concert 
The present (Fig. 37) and previous findings show that the PAF-induced edema is 
composed of three components, one that is directly related to increased permeability 
namely calcium, and two mechanisms that sensitize the cells to this response namely 
the reduction in NO (Fig. 30) and cAMP [152]. At the molecular levels, these 
responses appear to be mediated the ASM-dependent recruitment of Cav-1 and 
TRPC6 channels to caveolae and by the cyclooxygenase-dependent activation of 
EP3 receptors (Fig. 37). An important question is how these three events are related 
to each other. In the following we will discuss possible mechanisms of how these 
mechanisms interact: 
Hypothesis 1: PGE2 may regulate the activity of TRPC6 channels. This hypothesis is 
supported by the following findings: a) the EP3 receptor that partly mediates PAF-
induced edema formation is exclusively localized to the raft fractions [393]; b) in 
eryptosis triggered by PAF, the TRPC6 channel was activated by PGE2 [394-396]. 
Therefore it appears possible that in PAF-induced edema, the EP3-receptor leads to 
activation or sensitization of TRPC6 receptors (Fig. 43).  
Hypothesis 2: NO may regulate the activity of the TRPC6 channels. While it is well 
known that increased endothelial Ca2+ can promote eNOS phosphorylation and NO 
production [397], it is also established that NO can negatively regulate calcium influx 
and TRP channels. In particular, the elevated NO level stimulate guanylyl cyclases to 
produce cGMP, which activates multiple pathways and which may in fact also inhibit 
TRP channels. Both TRPC channels [398-399] and TRPV channels [351] were 
reported to be regulated by this negative feedback pathway. 
Thus, a negative feedback regulation seems to be in place: Normally the rise in 
[Ca2+]i provides a signal to reduce Ca2+-influx through a signal transduction pathway 
involving NOS-NO-cGMP-PKG and TRP channels. This inhibition of TRP channels 
would serve to protect the cells from the detrimental effects of excessive [Ca2+]i 
and/or NO [400]. It has been suggested that TRPC6 is inhibited by NO-cGMP-PKG 
                                                                                                                                                                  Discussion 
 87
related phosphorylation in both a heterologous expression system and vascular 
myocytes and that cationic currents due to TRPC6 activation are suppressed by the 
NO donor SNAP (S-nitroso-N-acetyl-penicillamine) [400]. A similar extent of 
suppression was also observed with a membrane-permeable analogue of cGMP, 
8Br-cGMP [398, 401]. The inhibitory effects of SNAP and 8Br-cGMP on TRPC6 
channel currents were strongly attenuated by the presence of inhibitors for guanylyl 
cyclase and PKG [398, 401]. In another study, in isolated mouse lungs challenged 
with elevated perfusion pressure, endothelial NO formation limited the permeability 
increase by cGMP-dependent attenuation of [Ca2+]I through TRPV4 channels; these 
findings were also confirmed by whole-cell patch-clamp of pulmonary microvascular 
endothelial cells [399]. 
In line with all these, further studies from our group (data not shown) show that cGMP 
attenuates the PAF-induced endothelial [Ca2+]i increase and hyperpolarizes 
endothelial cells in presence of the TRPC6-agonist hyperforin. All these findings put 
our finding that NO-depletion occurs simultaneous with the increase in calcium into 
perspective: the cessation of NO production by PAF can be interpreted as a measure 
to exclude the NO-dependent feedback on TRPC6-channels.  
 
 
 
Fig. 42: Mechanisms of PAF-induced hyperpermeability in the pulmonary vasculature, 
Summary of our current hypothesis. ASM: acid sphingomyelinase; COX: 
cyclooxygenase; PGE2: Prostaglandin E2; MLCK: myosin light chain kinase 
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5.4 Endothelial permeability regulation in the lungs and in extra-
pulmonary organs  
5.4.1 Regulation of vascular permeability by NO and calcium 
In the present work, it was shown that PAF causes a decrease in endothelial NO 
production. However, in the non-pulmonary circulation, where PAF alters vascular 
permeability and intracellular calcium with a similar time course as in the lungs, it 
affects NO production in the opposite direction leading to an increase (Fig. 43). 
Accordingly, NO-synthase inhibitors attenuated PAF-induced edema formation in the 
systemic circulation, in contrast to the lungs where NO donors were effective (Fig. 
43). In this chapter we will discuss these conflicting results  
 
 
 
Fig. 43: Effects of PAF on vascular permeability, NO formation and calcium influx. 
Experiments were performed in the extra-pulmonary organs following topical application of 
100 nMol/L PAF (A, C, E in hamster cheek pouch and G in mesentery microvessels) and in 
isolated perfused rat lungs challenged with 5 nMol PAF which after equilibration corresponds 
to 50 nMol/L (B, D, F, H). PAF was always added at t=0 or as indicated by the arrows. Panel 
A: Hamster cheek pouch: Extravasation of FITC-dextran expressed as integrated optical 
intensity (IOI) [402]. Panel B: Isolated perused rat lung: weight gain in PAF-treated (●) and 
control lungs (○). Panel C: Hamster cheek pouch: nitric oxide levels measured with a NO-
sensitive microelectrode [403]. Panel D: Isolated perused rat lung: endothelial nitric oxide 
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production assessed by DAF-FM fluorescence microscopy in control lungs (○), lungs treated 
with PAF (●) or 250 μM L-NAME (◊) as positive control for inhibited NO production. Panel E: 
Extravasation of FITC-dextran expressed as integrated optical intensity (IOI) in the hamster 
cheek pouch treated with PAF ± L-NAME (10 μMol/L) [402]. Panel F: Isolated perused rat 
lung: change in filtration coefficient (Kf) in lungs treated with PAF ± L-NAME (250 μM). Panel 
G: Mesentery microvessels: endothelial [Ca2+]i assessed by fura 2-AM fluorescence 
microscopy in PAF treated (●) microvessels [365]. Panel H: Isolated perused rat lung: 
endothelial [Ca2+]i assessed by fura 2-AM fluorescence microscopy in PAF tereated lungs. 
The data from the extra-pulmonary organs are shown as mean±SEM, the data from the rat 
lung as mean±SD. *: p<0.05 versus control, #: p<0.05 versus PAF. Data in panel D were 
analyzed by the Kruskal-Wallis test, data in panel F by two-sided t-tests and p values 
corrected for multiple comparisons according to the false-discovery rate procedure. Data in 
panel E were analyzed by the Student’s-Newman-Keuls test. 
 
In the isolated perfused lung preparation, PAF caused rapid edema formation and 
cessation of endothelial NO synthesis in venular capillaries within less than 5 min 
(Fig. 43 B and D); a similar instantaneous reduction in NO has been described in 
PAF-treated human mesangial cells in culture before [321]. In striking contrast to the 
lungs (Fig. 43, panel C), in the hamster cheek pouch [402-403], in perfused 
mesenteric venules [365], and in human umbilical vein endothelial cells (HUVECs) 
[404] PAF induced a marked increase in endothelial NO production. In the systemic 
microvasculature of the hamster cheek pouch, the increased leakage in response to 
PAF is inhibited by nitric oxide synthase (NOS) inhibitors [400, 402], and this 
inhibition is overcome by administration of the exogenous NO donor SNAP [400], 
indicating that enhanced NO production plays an obligatory role in PAF-induced 
leakage of systemic microvessels.  
This opinion is supported by studies in rat mesenteric microvessels [405], in the 
cremaster muscle of mice deficient in eNOS [406] and in vitro in monolayers of 
coronary postcapillary venular endothelial cells in which PAF induced a characteristic 
hyperpermeability that was abolished after depletion of endogenous eNOS (Fig. 43, 
panel E). In contrast, the present work revealed that PAF-induced edema formation 
in the lungs was not impaired by the NOS inhibitor L-NAME, but instead attenuated 
by the exogenous NO donor PAPA NONOate (Fig. 43, panel F); L-NAME even 
exacerbated the Kf and PAF-induced edema formation in the lungs. PAF caused a 
calcium influx and endothelial [Ca2+]i increase both in extra-pulmonary system and 
intact lungs (Fig. 43, panel G and H). 
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Fig. 44: Regulation of PAF-induced edema formation in different tissues. The abscissa 
shows putative NO concentrations [407]. The ordinate indicates increasing vascular 
permeability on an arbitrary scale. In rat and mouse lungs PAF leads to a decrease in NO 
formation that is related to edema formation. In extra-pulmonary tissues, such as the hamster 
cheek pouch, the mouse cremaster muscle and the mouse mesenteric venules [365, 405-
406, 408] PAF-induced edema is caused by increased endothelial NO production. 
 
Our explanation for these conflicting reports is that vascular barrier function in the 
lung and extra-pulmonary organs are maintained only if NO is kept at its proper 
physiological level, being neither too much nor too little (Fig. 44). Accordingly, both 
too much and too little NO can increase vascular permeability [376, 405-406] and NO 
synthase inhibitors can either attenuate [400, 402, 409] or aggravate [366, 410-411] 
pulmonary and extra-pulmonary hyperpermeability. 
An additional explanation might be the different time points studied and the 
numerous and diverse effects of NO on leukocytes and endothelial cells. Our model 
of the isolated blood-free perfused rat lung allows circumvention of most of these 
confounders. a) In vivo, the PAF-induced edema formation appears to consist of an 
early phase (~10 min) caused by a direct effect on the vascular endothelium and a 
later phase (~20 min) mediated by PAF-activated leukocytes [412]. The focus on the 
first 10 min and the absence of leukocytes in our model [413] allowed us to 
exclusively study the early effects of PAF on the pulmonary endothelium. b) blood-
free perfusion allows the exclusion of complications as NO effects on neutrophils. 
Another potential concern arises from the observation that NO is involved in the 
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regulation of alveolar epithelial barrier functions, and thus that the effect of PAPA-
NONOate might be on the alveolar epithelium rather than on the endothelium. 
Therefore, it was important to show that PAF does not cause alveolar edema or alter 
alveolar fluid absorption in our model (Fig. 24).  
PAF causes a rapid calcium influx and endothelial [Ca2+]i increase in both extra-
pulmonary and pulmonary endothelial cells (Fig. 43, panel G and H). Commonly it is 
thought that the increased calcium levels increase lung microvascular permeability 
via MLCK-activation and MLC phosphorylation and an actin-myosin contractile 
mechanism [66-67]. This mechanism appears to account for the PAF effects in the 
lungs, since the MLCK inhibitor ML-7 attenuated PAF-induced edema formation [350]. 
Contrasting the results in the lungs again, PAF did not cause MLCK phosphorylation 
in HUVEC [143] and ML-7 failed to affect PAF-induced hyperpermeability in rat 
mesenteric venules [146]. Thus again, a pattern of two differential pathways emerges 
such that in the lungs PAF increases microvascular permeability by an MLCK-
dependent mechanism that is facilitated by cessation of endothelial NO production, 
while PAF-induced hyperpermeability in many systemic microvessels is independent 
of MLCK, but instead requires endothelial NO production. Since Ca2+/calmodulin 
promotes eNOS phosphorylation and NO production in a rapid manner [397], this 
may explain the role of calcium in edema formation in extrapulmonary vessels. 
 
5.4.2 Role of caveolae, ASM and ceramide 
The regulation of NO production by ASM and ceramide again appears to differ in 
pulmonary and in extra-pulmonary vessels. Ceramide activates eNOS and stimulates 
endothelial NO formation in cultured bovine aortic endothelial cells (BAEC) [326, 
414], as well as in eNOS expressing chinese hamster ovary (CHO) cells [415-416]. 
Notably, the ceramide induced stimulation of eNOS in systemic endothelial cells is 
independent of Ca2+ regulation since it is unaffected by the intracellular Ca2+ chelator 
1,2-bis-o-aminophenoxyethane-N,N,N´,N´-tetraacetic acid (BAPTA) and not 
accompanied by a simultaneous [Ca2+]i signal [326]. In addition it also seems to be 
independent of the source of ceramide, since it is equally triggered by stimulation of 
both ASM and neutral sphingomyelinase (NSM) [417]. Taken together, 
sphingomyelinase-dependent ceramide formation causes divergent activation and 
inhibition of eNOS in systemic and pulmonary endothelial cells, which is likely to 
underlie the differential NO response and may contribute to the different forms of 
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hyperpermeability induced by PAF in these cells. The question to be addressed 
further concerns the mechanisms underlying the differential regulation of eNOS by 
ceramide. 
It is commonly accepted that direct interaction of eNOS with the scaffolding domain 
of Cav-1 keeps the enzyme in its inactivated, dormant status in the absence of 
stimulation. This concept is supported by the observation that administration of a cell 
permeable form of this scaffolding domain prevented the PAF-induced increase in 
vascular permeability in rat mesenteric venules probably by interception of the eNOS-
caveolin-1 interaction in caveolae [405]. In coronary postcapillary venular endothelial 
(CVE) cells and ECV304 cells studies, Sánchez and colleagues showed that eNOS 
translocation from caveolae to the cytosolic fraction was associated with increased 
NO production and a concomitant increase in endothelial permeability [375-376, 
418]. Inhibition of caveolar scission by transfection of the dynamin dominant-negative 
mutant dyn2K44A prevented the endothelial hyperpermeability in response to PAF 
and eliminated NO production [375-376].  
 
Fig. 45: regulation of NO production by caveolin. a) In isolated rat lungs, PAF causes a 
cessation of NO production by stimulating the acid sphingomyelinase (ASM)-dependent 
translocation of eNOS to caveolae. PAF also causes Ca2+-dependent activation of the MLCK 
that is thought to increase vascular permeability by endothelial cell contraction. b) In bovine 
CVEC and in ECV304 cells PAF stimulates NO production that depends on internalization of 
caveolae [408]. MLCK: myosin light chain kinase; CVEC: coronary postcapillary venular 
endothelial cells. 
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Thus internalization of caveolae appears to be necessary for PAF-induced NO 
production in CVE cells [375-376]. Internalization of eNOS is considered to allow for 
targeted NO delivery to subcellular structures and the subsequent increase in 
endothelial permeability by promoting the internalization or inhibiting the arrival of 
endothelial junctional proteins [375, 418]. NO driven S-nitrosylation of barrier-
regulating proteins could play a major role in this scenario, since it has been shown 
to be associated with increased vascular permeability in pathological conditions such 
as cerebral ischemia and reperfusion [419]. The notion that eNOS internalization and 
targeted NO delivery are critical for PAF-induced barrier failure in systemic 
endothelial cells is supported by the fact that PAF-stimulated NO synthesis does not 
cause hyperpermeability in cav1Y14F transfected cells in which caveolae are 
anchored to the plasma membrane [375]. In the lungs in contrast, caveolin and eNOS 
are recruited to caveolae, but are not internalized in response to PAF. As discussed 
this explains the rapid cessation of endothelial NO synthesis by the well-established 
interaction of eNOS inactivation with caveolin-1 [307, 317, 420] probably leading to a 
reduction in PKG-dependent TRPC6-phosphorylation and increased calcium influx   
[351, 358, 398-399, 421].  
 
5.5 Concluding remarks 
The pulmonary and the systemic circulation differ in many fundamental aspects such 
as the blood pressure (low versus high), the arterio-venous oxygen gradient 
(oxygenation versus deoxygenation), the response to hypoxia (vasoconstriction 
versus vasorelaxation [422]), and the endothelial permeability in response to 
histamine (no effect versus increased [423]), to name some of the most striking 
discrepancies. Another example of this dichotomy appears to be endothelial NO 
production in response to PAF: NO production decreases in lung endothelial cells 
and increases in the systemic circulation. Surprisingly, both responses have the 
same effect, in that they increase vascular permeability. Therefore, we conclude that 
vascular barrier function in both the lung and extra pulmonary organs is only 
maintained if NO is kept at its physiological level. A clinical implication of this insight 
is that it will be enormously difficult to treat diseases with a wide-spread increase of 
vascular permeability, such as sepsis, by NOS-inhibitors or NO-donors, because 
these agents will be barrier-protective in one vascular bed, but detrimental in another 
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Our conclusions relate specifically to the effects of PAF in dissimilar vascular beds. In 
pulmonary endothelial cells from intact lungs, PAF causes barrier failure by activation 
of cyclooxygenase and ASM resulting in the formation of PGE2 and ceramide. The 
latter increases endothelial permeability partly through activation of MLCK by 
stimulation of Ca2+ signalling and a concomitant inhibition of basal NO synthesis 
which is brought about by the parallel recruitment of caveolin-1 and eNOS to 
caveolae. Conversely, in endothelial cells of the extra-pulmonary system, PAF 
increases permeability by MLCK-independent formation. In these cells both PAF and 
possibly also ASM/ceramide increase endothelial NO synthesis. The PAF-induced 
stimulation of eNOS in the non-pulmonary endothelium is regulated by caveolar 
internalization, which simultaneously allows for targeted delivery of NO to subcellular 
targets which appears to constitute a prerequisite for the subsequent permeability 
increase. 
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6 Summary 
Platelet-activating factor (PAF) is a mediator of pulmonary edema in acute lung injury 
that increases pulmonary vascular permeability within minutes, partly through 
activation of acid sphingomyelinase (ASM). Caveolae are rich in sphingolipids and 
caveolin-1 (Cav-1) which binds and blocks eNOS. Caveolae also may act as entry 
portals for Ca2+. Therefore, we examined the relationship between ASM, Cav-1, 
eNOS and Ca2+. Experiments were performed in isolated perfused rat and mouse 
lungs. Caveolae from pulmonary endothelial cells were isolated after tagging them by 
perfusion with silica beads and followed by the detergent resistant membrane 
fractions preparation. Endothelial NO and Ca2+ levels were determined by in situ 
fluorescence microscopy. 
PAF treatment induced edema formation and decreased endothelial NO formation. In 
caveolae fractions from pulmonary vascular endothelial cells (isolated from perfused 
rat lungs), the abundance of caveolin-1 and eNOS increased rapidly after PAF 
perfusion. Restoration of endothelial NO levels with exogenous NO donor mitigated 
the PAF-induced edema. PAF treatment increased the ASM activity in caveolar 
fractions and perfusion with ASM decreased endothelial NO production. 
Pharmacological inhibition of the ASM pathway with imipramine, D609 or 
dexamethasone blocked the PAF-induced increase of caveolin-1 and eNOS in 
caveolae, as well as the decrease in NO production and edema formation. 
PAF treatment also increased endothelial [Ca2+]i. This response was abrogated by 
Imipramine, the ASM-inhibitor ARC39 and in ASM-deficient mice. Conversely, 
endothelial [Ca2+]i was increased by direct perfusion with ASM. Both the PAF-
induced [Ca2+]i increase and edema formation was blocked by the unselective TRPC 
inhibitor SKF96365. Screening for a variety of TRPC channels in caveolar fractions 
from pulmonary vascular endothelial cells revealed that PAF increased the 
abundance of TRPC6 channels, and this response was abrogated ARC39. The PAF-
induced increase in endothelial [Ca2+]i and the edema formation was absent in 
TRPC6-deficient mice.  
We conclude that PAF causes ASM-dependent enrichment of caveolin-1 and 
TRPC6-channels in caveolae of endothelial cells. This leads to decreased NO 
production and increased Ca2+ levels. We propose that the decreased NO levels 
sensitize endothelial cells for Ca2+-dependent mechanisms of endothelial 
permeability. 
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